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NUCLEOTIDE EXCISION REPAIR, CROSSLINK REPAIR AND
TRANSCRIPTIONAL FUNCTION OF XPA IN HUMAN CELLS

Mandira Manandhar, PhD
Supervisory Professor: Richard D. Wood, PhD

Nucleotide excision repair (NER) in mammalian cells includes xeroderma
pigmentosum group A protein (XPA) as a core factor. XPA and other NER
proteins have been detected previously at some active promoters, and NER
deficiency is reported to decrease activated transcription of selected genes. To
determine the global extent of XPA influence on transcription, we analyzed the
human transcriptome by RNA sequencing. We first confirmed that XPA is
confined to the cell nucleus even in the absence of external DNA damage, in
contrast to previous reports that XPA is normally resident in the cytoplasm and is
imported following DNA damage. We then analyzed four genetically matched
human cell line pairs deficient or proficient in XPA. At a false discovery rate of
0.05, 325 genes were common in all four pairs with a significant XPA-dependent
directional change in gene expression. These genes were highly represented in
pathways for the maintenance of mitochondria, metabolism and neurological
system. Only 27 genes were regulated by more than 1.5 fold change. The most
significant hits were AKR1C1 and AKR1C2, involved in steroid hormone
metabolism, and the corresponding proteins were lower in XPA-deficient cells.
Transactivation by retinoic acid caused a modest enrichment of genes involved in
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transcription-related functions in XPA proficient cells. The results show that XPA
status significantly influences a small subset of human genes that are important
for mitochondrial and metabolic functions. The results may help explain defects
in neurological function and sterility in individuals with xeroderma pigmentosum
(XP).

An NER deficiency enhances sensitivity of mammalian cells to DNA
interstrand crosslinks (ICL)-generating agents. I found that XPA is retained on
damaged DNA following exposure to UVA-activated psoralen, and investigated
repair of a triplex forming oligonucleotide (TFO)-directed psoralen ICL. A TFOdirected psoralen DNA ICL was constructed in closed-circular DNA. In NER
proficient human cell extracts, incisions were detected on both strands of the
damaged DNA 3’ to the psoralen ICL. Incision sites on the TFO bound strand
were flanked by incision sites 40-42 nucleotides away from the ICL, with incisions
10-12 nucleotides away on the other strand.
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Chapter 1. Introduction

1.1. DNA-interstrand crosslink in mammalian cells

DNA-interstrand crosslinks (ICLs) form a bridge between the two strands
of the DNA double helix, blocking transcription and DNA replication (Figure 1).
ICLs are formed by exogenous sources such as mitomycin C (MMC), nitrogen
mustard, cisplatin compounds and natural compounds such as psoralen.
Endogenous metabolites also form ICLs, including nitric oxide and the lipid
peroxidation products acrolein, crotonaldehyde and malondialdehyde (1, 2). ICLinducing agents are among the most genotoxic and mutagenic compounds as
compared to agents that introduce only monoadducts (3). ICL-causing nitrogen
mustards such as cyclophosphamide and melphalan are widely used for the
treatment of leukemia as well as solid tumors. Similarly mitomycin C, cisplatin
and carboplatin are used for treating testicular and ovarian cancers and psoralen
is used to treat cutaneous T cell lymphoma (2).

However, it is not fully understood how these ICLs are processed in
mammalian cells. In replicating cells, the Fanconi anemia pathway plays major
role in the ICL repair. The FA complex consists many proteins and 8 of them
(FANCA, B,C,E,F,G,L and M) form a core complex. Ubiquitination of FANCD2
and FANCI by the core complex occurs upon encountering ICL blockage, which
activates the repair process (4). Initially FANCM makes a complex with FAAP24
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protein that causes the activation of the recruitment of other FA proteins to the
damage site. These proteins form a complex and stabilize the replication fork,
which activates ATR mediated cell cycle signalling (5-7). Monoubiquitination of
FANCD2 is the key for the recruitment of nucleases such as FAN1 and SLX4 (8,
9). ERCC1-XPF complex and MUS81-EME is also assembled for the processing
of the ends and the unhooking of the crosslink (6). The unhooked structure is
cleaved by NER (10, 11) and the double strand break is repaired through
homologous recombination (HR) (12, 13). Translesion synthesis (TLS)
polymerases like Rev1-Rev3L are involved in NER process after unhooked
structures are removed (14) and FA complex is necessary for their recruitment
(15, 16).

There is also evidence that nucleotide excision repair (NER) is an
important repair pathway for ICL in nonreplicating cells. NER dual incision is well
studied in E. coli. In mammalian cells, NER deficient cells are sensitive to ICL
inducing agents (10, 17, 18) . Also, ICL repair defects have been shown in NER
defective cells by various researchers. ICL formed by psoralen could not be
removed in XPA deficient cells in a gene specific assay (19). XPA and XPF
defective ceIls were defective in unhooking ICL formed by psoralen (18) and
formed by cisplatin in XPG defective cells (20).

Incision is an important step in the processing of ICL as it determines how
ICL will be being processed. Some studies have been done focusing on incisions
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around ICLs. Bessho et al (1997) found that NER in human cell extracts
introduced two incisions separated by about 21 nt on the 5’ side of a psoralen
ICL (21). Smeaton et al. (2008) used a crosslink placed in a 150-mer linear
duplex and verified the presence of these futile incisions (22). They also
suggested that strong incisions were present about 1-5nt on the 5’ side and 3-5nt
on the 3’ side of an ICL. The origin of these incisions is not known. Either they
are artifacts produced by unsuitable ICL substrates for incision assays or if they
are real, they should be further studied to find their role in the processing of an
ICL. R. Legerski found a repair patch in a circular psoralen ICL substrate that
runs from 5’ side to 3’ side of the ICL suggesting a dual incision (23). Thus a very
controlled and precise mapping study of ICL repair in mammalian cells is
necessary in order to fully understand the mechanism of ICL processing. This
understanding will allow the manipulation of different steps of processing of an
ICL.

ICL forming agents have been effective in treating some forms of cancer,
but they are not so useful in others. In addition, resistance to ICL forming
chemotherapies is a major problem for treatment of cancer. This problem could
be solved to a greater extent, if we understood the details of processing of ICL.
Study of the repair of a site-specific ICL is a controlled way of exactly mapping
out how cells process ICL damage.
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A psoralen ICL was studied here, targeted by a triplex-forming
oligonucleotide (TFO). In addition to directing psoralen to a specific site of DNA,
TFOs have a very important therapeutic potentiality. TFOs can be used to
targeted gene alterations. For example, TFO mediated correction of AID deficient
human lymphocytes and p53 mutant glioblastoma cells have been demonstrated
(24). There are also studies showing that a TFO might enhance the recruitment
of repair proteins. In E. coli, a TFO-directed psoralen ICL is an NER substrate
and leads to significantly more incision products than psoralen by itself (25). NER
was indicated to be involved in TFO mediated homologous exchange, and
sequence specific mutagenesis was shown to be dependent on the NER protein
XPA (26, 27).
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A.

B.
Psoralen$

TFO$

Duplex$DNA$strands$

FIGURE 1. Chemical structure of psoralen DNA ICL and space filling model
of a TFO-psoralen DNA ICL
A. Structure of an interstrand crosslink formed by HMT psoralen on thymines (T)
on both strands of DNA. The furan ring of psoralen binds to one thymine and the
pyrone ring of psoralen binds to a thymine on the complementary DNA strand. B.
Space filling model of TFO binding to duplex DNA in the major groove. Yellow
indicates psoralen bound at 5’ end of the TFO, green and blue indicate two
strands of DNA.
FIGURE 1B is adapted from Christensen LA, Wang H, Van Houten B, Vasquez
KM: Efficient processing of TFO-directed psoralen DNA interstrand crosslinks by
the UvrABC nuclease. Nucleic Acids Res 2008, 36(22): 7136-7145.
Permission has been acquired from the journal to use this figure.
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1.2. Nucleotide excision repair pathway and XPA protein

Nucleotide excision repair is the DNA repair pathway for a wide range of
DNA lesions. The lesions include pyrimidine dimers formed by UV radiation, and
bulky adducts formed by many chemicals and some endogenous metabolites (28,
29). NER has two sub-pathways: Global genomic NER (GG-NER) and
transcription coupled NER (TC- NER). The difference in the two pathways lies in
the recognition of the damage. GG-NER recognizes the distortion in the helix of
DNA in all parts the genome. TC-NER is activated when RNA polymerase II is
stalled during the elongation of transcript due to the presence of DNA damage on
the template strand. The overall function of mammalian NER is to precisely
remove the damaged nucleotides as a 24-32 base long single-stranded
oligonucleotide and then to restore the DNA with undamaged nucleotides. About
30 polypeptides are involved in the whole process of NER, which make
successive complexes necessary for damage recognition, incision and
restoration (28, 30, 31) (Figure 2).

In GG-NER, the initial damage recognition is done by protein complex
called XPC-RAD23B (32). XPC is sequestered by damaged DNA and its binding
to damaged DNA triggers the further repair process (32). RAD23B enhances the
DNA binding activity of XPC, stabilizes the complex and protects it from
proteasome degradation (28). It does not come in direct contact with DNA and is
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not immobilized on the damaged DNA but it is released after XPC binds to the
DNA (33). An N-terminal region (amino acids 154-334) of XPC binds to XPA (34).

After DNA distortion is recognized, TFIIH is recruited to the damaged site.
TFIIH is a ten subunit complex consisting of proteins XPB, XPD, p62, p44, p34,
p52, p8 and a cdk activating kinase (CAK) with subunits Mat1, Cdk7 and CyclinH.
TFIIH is a general transcription factor but also acts as a core NER factor for DNA
repair. The XPB subunit of TFIIH is a 3’à5’ DNA helicase and XPD is a 5’à3’
helicase. TFIIH unwinds DNA at the damaged site to form a single stranded
region, in an ATP dependent manner (35, 36). RPA and XPA interact with TFIIH
in the pre-incision complex. RPA is a single stranded DNA binding protein and
consists of 3 subunits with multiple cellular functions (37). RPA helps to form a
stable pre-incision bubble with four functional DNA binding OB
(oligonucleotide/saccharide binding)-folds present in its p70 and p32 subunits.
These interact with DNA in a polar manner (5’à3’) (38, 39). They occupy 30
nucleotides on the undamaged strand and thus protect this strand from
degradation by nucleases as well as facilitate the precise positioning of the
endonucleases at 5’ and 3’ side of the adduct.

XPA protein has increased affinity towards DNA structures such as
distortion of the helix due to damage of DNA. Thus XPA is part of the
confirmation process that detects the structural DNA distortion caused by DNA
damage (40). It directly interacts with damaged DNA (41, 42) at the junction of
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single strand and double strand (43). XPA is recruited to the damaged site by
TFIIH complex through its p8 and p52 subunits (44, 45). Interestingly XPA is also
reported to interact with another transcription factor TFIIE, however the function
of the interaction is not clear (46). XPA is a small protein with 273 amino acids,
does not have any enzymatic activity but interacts with other NER proteins
playing role as a major scaffolding protein in NER. XPA coordinates with RPA to
facilitate the functions of nucleases for NER.

XPA has a globular central domain (98-219) with a C4 type zinc finger
motif in the N terminal region and a cleft in the C-terminal region. XPA has many
protein binding interaction domains (47-50) (Figure 3). Interestingly XPA point
mutations associated with xeroderma pigmentosum are principally in the central
domain (50, 51). Mutations compromising or eliminating the DNA binding region
are associated with the most severe XP syndromes including accelerated aging
and neurodegeneration (51). XPA also interacts with XPE at XPA residues 185226, and the mutation at this site has been reported to cause failure in the
removal of cyclobutane pyrimidine dimers (CPD) (52). XPA interacts with RPA2
primarily via XPA residues 29-46 and XPA residues 98-219 secondarily or
weakly interact with RPA1 (49, 53). XPA has a nuclear localization (NLS)
domain at 30-42 aa region. However it has been shown that when mutation of
XPA at this region affects its localization in the nucleus, these residues were not
found to be essential for DNA repair (54).
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ERCC1-XPF nuclease is recruited to the damage site by interaction of
XPA protein amino acids 96-114 and ERCC1 residues 92-119 (48).
XPA contains a PCNA binding site called an APIM (AlkB homolog PCNA
interacting motif) sequence but the functional aspect of the interaction is not clear
yet (55). XPA also interacts with other proteins such as ATR and PARP that are
not involved in NER. ATR phosphorylates XPA at Ser196. XPA has a PARP
binding motif at 213-237. PARP can inhibit the DNA binding activity of XPA (56).

Mutations in XPA cause XP, with a severity that varies according to the
particular mutation. A common consequence of XPA mutations is sensitivity to
UV radiation, leading to skin abnormalities and a predisposition to skin cancers.
The most severe cases result in progressive neurodegeneration and a higher
incidence of melanomas (57-59). The reason behind the variation in the severity
in the XPA deficient patients is still to be studied. This could be the result of
expression of different fragments of XPA protein with different functions.
Truncation of Exon 1 or Exon 6 which is thought to be dispensable for NER, have
been reported to yield only mild XP syndrome whereas deletion of Exon 2-5
which encodes the DNA binding domain and is essential for NER has been
reported to cause a severe form of XP (51, 60, 61).

ERCC1-XPF and XPG are structure specific endonucleases that cleave
on the 5’ side and 3’ side of an adduct on the damaged DNA strand during
nucleotide excision repair. ERCC1-XPF protein has multiple functions besides a
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role in NER. The endonuclease activity of this complex can act on different
substrates including those formed by the Fanconi anemia pathway during repair
of ICL-induced DNA damage, 3’ ends during homologous recombination and
hairpin structures (62), removal of non-homologous ends during non-homologous
end joining (63-65) and maintenance of telomeres (62, 66). Disruption of ERCC1
has severe consequences. Mice with disrupted ERCC1 die before weaning from
liver disorder and other organ failure (67, 68). Mice with a knock out of the XPG
gene die due to a developmental defect in intestine formation (69) and humans
with XPG mutations sometimes have a short life-span and developmental defects
similar to Cockayne syndrome, indicating that XPG has a second function other
than in NER (70).

CSA and CSB proteins are essential for transcription coupled NER.
Mutation in CSA and or CSB genes cause a severe condition called Cockayne
syndrome which is characterized by severe neurodegeneration, developmental
defects, accelerated aging (progeroid syndrome) and UV radiation sensitivity (71).
The mixed cases of CS/XP are even worse, with both CS and XP symptoms
caused by specific mutations in the XPB, XPD or XPG genes. These individuals
have an increased photosensitivity and more cancer-proneness as they have
defects in both TC-NER and GG-NER (71).
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FIGURE 2. Diagram of NER in mammalian cells showing stepwise events.
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This diagram shows the GG-NER pathway. (i) XPC-RAD23B protein complex
recognizes the distortion of DNA helical structure caused by the lesion. TFIIH is
recruited by XPC-RAD23B complex at a site of damage. (ii) The NER proteins
XPA, RPA, XPG and ERCC1-XPF are recruited at the damaged site to form a
preincision complex together with TFIIH complex. The two DNA strands are
separated in an ATP dependent manner to form a bubble (72). (iii) The ERCC1XPF nuclease makes an incision at the 5’ side of the lesion and the XPG
nuclease produces the incision at the 3’ side. This process of producing incision
at both sides of the lesion simultaneously is referred as dual incision. The CDK7activating (CAK) subunits of TFIIH are detached from the precision complex after
it is formed (73). Dual incision releases a fragment of damaged DNA about 27-32
nucleotides long. This is a characteristic of NER in mammalian cells. (iv) A DNA
polymerase is loaded by PCNA and fills the gap made by the incisions.

FIGURE 2 is adapted from Wood, R. D. (2010): Mammalian nucleotide excision
repair proteins and interstrand crosslink repair. Environ Mol Mutagen 51(6): 520526
Permission has been acquired from the journal to use this figure.
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1.3. Transcriptional role of XPA, a major NER protein

Nucleotide excision repair (NER) is the only pathway that mammalian cells
have available for the removal of DNA lesions arising from ultraviolet (UV)
radiation damage. NER also repairs helix-distorting lesions produced by other
types of radiation and some chemicals. In eukaryotes, most of the components of
the NER machinery have major additional biological functions that are essential
for normal viability. This has profound consequences for cells or organisms with
mutations in NER genes. The ten subunits of TFIIH form a core initiation factor
for basal transcription of all mRNAs, for example, and XPG also has a
transcription-related function (74). ERCC1-XPF participates in some homologous
recombination reactions and in crosslink repair (62). As a consequence,
complete disruption of some NER components is incompatible with cellular
survival or embryonic development (for example, TFIIH subunits or RPA), while
perinatal lethality occurs following disruption of other components (ERCC1, XPF,
XPG). Mutations that partially disable these factors can lead to severe diseases
in human beings.

Complete disruption of two major NER factors is tolerated, however. One
of these is XPC, part of a distortion recognition complex. XPC disruption causes
xeroderma pigmentosum in humans, but is relatively less severe than other
forms because a transcription-coupled form of NER remains intact. Nevertheless,
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even XPC is reported to play a dual function as a component of a transcription
complex for specific genes (75).

The other NER factor that can be completely inactivated without impairing
cell viability is XPA. This is notable, as XPA is absolutely required for NER. It is a
scaffold protein that contacts many of the other factors in NER and binds to DNA
(Figure 3). As a consequence, xeroderma pigmentosum (XP) group A patients or
mice without XPA function have no NER activity. Because each of the other NER
factors has an identified additional function in cells, it is important to consider
whether XPA also has a significant biological function other than NER. Broadly, a
complete XPA defect has no major effect on mammalian development, growth or
cellular function. Patients with mutations that completely ablate XPA function are
born, develop normally and live for several decades. Similarly, mice with
complete XPA defects are born, develop normally, and have a near-normal
lifespan, with a low background of spontaneous tumors occurring later in life.

XPA patients often succumb to metastatic UV radiation-induced skin
tumors. This can be delayed by protection of individuals from sun exposure. In
addition, many XPA patients with loss of XPA function show accelerated
neurological deterioration over decades, initially characterized as de SanctisCacchione syndrome (57). Retention of a small amount of XPA function results in
much milder symptoms (76). A likely explanation for the origin of the neurological
impairment is the accumulation of genomic DNA lesions over decades in non-

	
  

14

replicating neural cells that can only be repaired by NER (77). Prime candidates
are the cyclopurines (78) induced by reactive oxygen species, which are repaired
by NER and cannot be removed by other repair systems (78, 79). XPA-defective
mice, with a much shorter lifespan, do not appear to exhibit these neurological
deficits (80).

Nevertheless, a few observations have suggested that XPA might have
additional functions beyond NER. At several tested promoters, all NER proteins
including XPA can be detected by chromatin immunoprecipitation. The basal
transcription factor TFIIH is expected to be present at promoters, and XPA may
be detectable because it binds to TFIIH and associated proteins. However at
least one result indicated that XPA depletion affects retinoic acid (RA) – induced
transcription of some genes (81). Indeed, depletion of XPA reduced RA-activated
transcription of RARB, PPAR, and HMGCS2. Moreover, a study comparing XPA
proficient and deficient cells by microarray analysis found changes in gene
expression associated with XPA status, and indicated that XPA-deficient cells
have mitochondrial dysfunction with defects in pathways of mitophagy (82), a
condition that could impact neural health. Decline of mitochondrial activity is the
hallmark of many neurological diseases, and neurons are the most sensitive to
mitochondrial dysfunctioning (83). These studies indicate the possibility of
mitochondria being affected when NER proteins are defective. The syndromes
observed in NER-deficient cases in humans and mice are mainly due to the
inability to repair DNA damage but more studies are necessary to understand the
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mechanisms of all the syndromes. An RNA- sequencing study on XPD/CS
patient cells, after UV exposure, suggests that the syndromes are not solely due
to DNA repair defects but also due to other transcriptional dysfunctioning (84). It
is very intriguing to see if a defect in NER proteins causes significant changes in
expression of genes in human cells.

Nucleotide excision repair (NER) proteins XPC, XPA, ERCC1-XPF, XPG,
TFIIH and CSB have also been reported to play an important role in the
regulation of nuclear receptor-dependent genes (81, 84-88). Down regulation of
any of these NER factors have shown to decrease the transcription of several
genes as well as impeding of the recruitment of the other NER factors at the
transcription sites (85). It is interesting that NER proteins play a significant role in
modulating the transcription of some genes and raises the question of whether
the whole genome is affected.

However, no study has been done in order to pursue genome wide
changes in the transcriptome in absence of specific NER proteins in absence of
any genotoxic challenge. To specifically investigate the extent of a possible
transcriptional defect in XPA-deficient cells, we examined genome wide
expression of transcribed genes by RNA-Seq analysis.

Based on previous studies (81, 82, 85-88), we expected that an XPA
defect might result in down regulation of genes responsible for mitochondrial,
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metabolic and neurological functions. We also transactivated cells with retinoic
acid (RA), which is the ligand for receptors including PPAR and RAR. The
products of the genes expressed by the activation of these receptors are involved
in many cellular functions such as cell differentiation, cell proliferation, apoptosis
and metabolism.

1.4. Localization of XPA protein

As described above, XPA has multiple functions, including a novel
transcriptional role, which we are actively pursuing. In order to have a direct role
as a transcription factor, XPA would have to be present in the nucleus where
transcription takes place. Although XPA is localized in the nucleus under
standard fixation conditions, we were concerned about reports that XPA is
normally resident in the cytoplasm, and is only recruited to nuclei following UV
radiation exposure (89, 90). Notably, in those studies, cells were first briefly
exposed to wash buffers containing Triton X-100 detergent or the milder fixation
agent methanol (89, 91), or with 0.05% NP-40 detergent (90). It is possible that
previous observations suggesting nuclear import of XPA following UV radiation
may have been misinterpreted because of nuclear leakage.

Nuclear pores are complex structures composed of 50 -100 different
proteins in vertebrates, making large pores through which small proteins less
than 50 kDa can passively pass. Nuclear pores have a diameter of about 120 nm
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and a molecular weight of about 125 million dalton (Da) (92). Detergents used in
different cellular studies can form micelles in the nuclear membrane and make it
even easier for the small proteins to leak out of the nucleus. The permeabilization
with detergents like NP-40 or Triton-X-100, which are non-selective in nature
could lead to false results regarding the localization of the proteins (93). Studies
have shown leaking of unassembled proteins from the nucleus to the cytoplasm
by detergent extraction (94).

UVC radiation exposure to cells leads to two major kinds of DNA
photoproducts (6-4) photoproducts and cyclobutane pyrimidine dimers (CPD) (95,
96). 80% of the adducts are CPDs and 20% are 6-4 Photoproducts (6-4PP) (29,
97). XPA is involved strongly in repair of these photoproducts as NER pathway is
the major DNA repair pathway for both kinds of DNA damage. We hypothesized
that during the repair process, XPA may be strongly recruited to sites of DNA
damage, inhibiting leakage even following the use of detergent. This would give a
different interpretation than hypothesizing that XPA is imported to the nuclei after
exposure to UV radiation.
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FIGURE 3: Diagram of XPA with the interaction with other proteins

At the top, the diagram shows human XPA protein with location of the central
globular core in relation to the six coding exons (gray). The locations of the
nuclear localization signal (NLS) and zinc finger (Zn2+) are shown. The bottom
part of the panel shows mapped regions of XPA that interact with other proteins.

FIGURE 3 is adapted from Sugitani N, Sivley RM, Perry KE, Capra JA, Chazin
WJ: XPA key scaffold for human nucleotide excision repair. DNA Repair (Amst)
Permission has been acquired from the journal to use this figure.
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Chapter 2. Methods and Materials

2.1. Preparation of samples for the next generation sequencing of RNA
from XPA deficient and proficient human cell lines

2.1.1. Cell lines

Four human cell lines deficient in XPA and their complementary XPAproficient cell lines were used. SV40-immortalized human fibroblast cells from
patients deficient in XPA (XP12RO and XP2OS) (98) and XPA-proficient
(XPA/XP12RO and XPA/XP2OS) cell lines complemented with XPA cDNA were
kindly provided by Dr. Masafumi Saijo, Osaka University. The mutations in
XP12RO and XP2OS are also shown in Figure 4A. Only 10% of our initial culture
of XPA/XPA12RO cells expressed XPA as shown by an immunofluorescent
assay with 12F5 anti-XPA antibody. We recloned XPA/XP12RO obtaining clone
2, which uniformly expresses XPA. All experiments reported here used clone 2 of
XPA/XP12RO as the XPA-proficient cell line paired with XP12RO. HeLa S3 cell
line was from laboratory stock. XPA disrupted HeLa S3 cell lines KO142 and
KO38 were derived by CRISPR-Cas9 targeting technology by the Gene Editing
and Cellular Model Core Facility at the University of Texas MD Anderson Cancer
Center (Figure 4B). XP12RO and XP2OS and the complemented XPA cell lines
were grown in DMEM-high glucose (Sigma D5796) and HeLa S3, KO142 and
KO38 in RPMI-1640 25 mM HEPES (Sigma R4130) medium. All cells were
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grown in medium containing 10% FBS, 1% streptomycin/penicillin solution at 37
ºC and 5% CO2.
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FIGURE 4. XPA disruption in proficient and deficient cell lines used in the
study.
A. The exon-intron structure of the human XPA gene showing the sites of the
causative XPA mutation in each XPA-deficient cell line used here. B. Location of
CRISPR-Cas9 mutations generated in the XPA gene of HeLa S3 cells. Two
mutated HeLa cell lines were obtained using two guide RNAs (gRNA). KO142
had the indicated 18 bp deletion in both alleles, and an A164G mutation leading
to a Q16R amino acid change in one allele. KO38 had a deletion of C168
(∆C168) leading to early termination in both alleles and a C142T mutation
leading to a P9S amino acid change in one allele.
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2.1.2. Immunoblotting

Anti-XPA antibodies used were rabbit polyclonal CJ1 (99), mouse
monoclonal 12F5, and rabbit polyclonal GTX103168 (Cat. No. GTX103168,
GeneTex). Other antibodies used were mouse monoclonal to AKR1C1 (Cat. No.
GTX53684, GeneTex), rabbit polyclonal to AKR1C2 (Cat. No. 13035, Cell
Signalling Technologies Inc.), rabbit polyclonal to AKR1C3 (Cat. No. ABS1172,
EMD Millipore), and mouse or rabbit α-tubulin (Sigma Aldrich). Mouse
monoclonal 1E4 (Trevigen) to XPF was a gift of Dr. Laura Niedernhofer. Cell
lysates were prepared by lysing 106 or 107 cells in lysis buffer (500 mM KCl, 20
mM Tris–HCl [pH 8.0], 5 mM MgCl2, 10% glycerol, 1 mM PMSF, 0.1% Tween 20,
10 mM β-mercaptoethanol) by pipetting up and down and then sonicated on ice
(45 sec with 15 sec intervals, for 2 times at 1 amplitude). Lysates were then
mixed with SDS loading buffer for 3 min at 95 °C before loading onto a 4-20%
gradient polyacrylamide gel. Proteins were transferred to a PVDF (polyvinylidene
fluoride membrane) for 1 hr in transfer-buffer (Tris-glycine with 20% methanol)
cooled on ice. The blots were blocked with 10% non-fat dairy milk for 2 hr at
room temperature and washed 3 x 10 min with TBS-T (Tris buffered salineTween 20). Membranes were incubation with primary antibodies diluted as
follows (CJ1; 1: 10000, 12F5; 1: 5000, GTX103168; 1: 1000, XPF 1E4; 1:2000,
AKR1C1; 1:1000, AKR1C2; 1: 500, AKR1C3; 1: 1000, α-tubulin; 1:8000).
Membranes were incubated overnight at 4 °C except for tubulin, which was for 20
minutes at room temperature. Then they were washed 3 x 10 min and incubated
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with mouse or rabbit IgG secondary antibodies (1:10,000) at room temperature
for 2 hr, washed and treated with Pierce Western blot signal enhancer (Thermo
Scientific Inc.) and then exposed to x-ray film.

2.1.3. UVC clonogenic survival assay

The UVC clonogenic survival experiments were performed using two 15 W
germicidal lamps emitting predominantly 254 nm light adjusted to a fluence of 0.3
J/m2/s. Cells were plated onto 10 cm dishes at densities of 1-5x105 cells per plate
and incubated overnight prior to treatment. The plates were swabbed around
their perimeters with sterile cotton swabs, growth media aspirated, the attached
cells rinsed once with sterile phosphate buffered saline without magnesium or
calcium (PBS) and irradiated with lids off through 4 ml of PBS. Following
treatment, the PBS was aspirated and cells were detached by trypsin-EDTA
treatment, passed through a 23 gauge needle, diluted, counted using a Beckman
Coulter Particle Counter Z1 Single, and plated at the appropriate cell number for
the given dose, in triplicate, into 10 cm plates containing 10 mL of growth
medium. Following incubation for 12-17 days, colonies were rinsed with PBS,
fixed with methanol, stained with 0.5% crystal violet in ethanol and counted
manually. The original plating counts and colony counts were used to determine
the plating efficiency and the % survival.
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2.1.4. NER extracts and assays

Whole cell extracts of HeLa S3 and KO38 were prepared as described
(100, 101). A protein concentration of at least 20 mg/ml was obtained in each
extract. A single 1,3 (dGpTpG) cisplatin intrastrand adduct substrate was
prepared and tested in an NER dual incision assay using the end-labelling
method (102, 103). Briefly, the reaction mixture (10 µl) consisted of 50 ng of PtGTG or control substrate, 40-45 µg of whole cell extract protein, in the NER
buffer with final concentration of 45 mM HEPES-KOH (pH 7.8), 70 mM KCl, 7.5
mM MgCl2 , 0.9 mM DTT, 0.4 mM EDTA, 2 mM ATP, 2.5 µg of creatine
phosphokinase, 3.4 % glycerol and 18 µg of bovine serum albumin. An
oligonucleotide containing G-overhang was used to detect the dual incision
product by incorporating complementary [α- 32P] dCTP. NER dual incision
complementation was done using purified XPA protein. For XPA purification, cell
growth, induction, and lysis was performed as described (104). The sonicate was
spun down at 15,000 x g, 30 min at 4 oC. Supernatant was incubated with HIS
Select Nickel Affinity Gel (Sigma) for 3 hr at 4 oC. The protein was eluted by
gravity flow with buffer containing 50 mM sodium phosphate (pH 8.0), 100 mM
KCl, 0.01% NP 40, 1 mM EDTA, 10% glycerol, and 250 mM imidazole. Fractions
were pooled and the buffer was exchanged to 25 mM HEPES KOH (pH 7.8),
10% glycerol, 0.4 mM EDTA, 1 mM DTT, and 0.5 M KCl.
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2.1.5. Immunofluorescence assay

Cells were washed 3 x 3 min with phosphate buffer saline (PBS) followed
by fixation with 4% formaldehyde for 10 min at room temperature. The fixed cells
were washed twice with 0.2% Triton-X 100 in PBS at room temperature for 3 min
followed by washing twice with PBS for 3 min. The cells were blocked with 5%
normal goat serum for 30 min at room temperature followed by two washes with
PBS for 3 min each. Incubation with 1:10,000 dilution of anti-XPA antibody 12F5
was done overnight at 4 °C on a shaker. Followed by a wash with PBS and
incubation with goat anti-mouse Alexa-Fluor 488 labelled IgG at a 1: 2000
dilution at room temperature for 2 hr, washed with PBS, incubated 10 min with 1
mg/ml DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride from Molecular
Probes) and washed with PBS. The slides were covered with mounting media
and then coverslips.

2.1.6. XPA-extraction immunofluorescence assay

In experiments observing extraction of XPA from the nucleus into the
cytoplasm, the cells were exposed to 0.05% NP-40 detergent in PBS for 10 sec
twice and fixed immediately with 4% formaldehyde for 10 min at room
temperature followed by two washes of 3 min each with PBS. The fixed cells
were blocked with 5% goat serum and staining was accomplished as described
above for normal immunofluorescence.
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2.1.7. UVC exposure

40,000 cells were plated on 18 mm x 18 mm coverslips in 35 mm diameter
petri dishes. After overnight incubation, the plates were washed twice with PBS
for 3 min each time and exposed to UVC for 5 J/m2, 20 J/m2 or 60 J/m2. Medium
was added back to the cells and incubated for 1 hr at 37 °C. Immunofluorescent
analysis was carried out as described above.

2.1.8. PUVA treatment

40,000 cells were plated on 18 mm x 18 mm coverslips in 35 mm diameter
petri dishes at 37 °C overnight. Cells were washed twice with Hank’s balanced
salt solution (HBSS) and incubated with 10 µM of 4'-Hydroxymethyl-4,5'-8trimethylpsoralen (HMT) in HBSS or HBSS alone for 30 min at 37 °C. The cells
were exposed to UVA for 30 min at 10 J/m2/s and washed with HBSS to remove
free psoralen. A second UVA dose of 18 kJ/m2, 36 kJ/m2, 54 kJ/m2 or 10.8 kJ/m2
was delivered to the cells on plates on ice. Media was placed back on the plates
and incubation continued for 1 hr at 37 °C. Cells treated with only psoralen were
kept in HBSS for the same time as for the corresponding PUVA treatments.
Immunofluorescent analysis was performed as described above using the
flourochromes A4 FLUO (blue) for DAPI and GFP FLUO (green) for XPA. The
images were acquired with a Leica DMI6000 microscope and objective lenses
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(magnification/numerical aperture) HCPLAN APO 10X/0.03 or HCX PL
FLUOTAR 20X/0.07. Dry imaging medium was used at room temperature. A
Leica DFC360 FX camera captured the images and Leica Application Suite X
(LAS X) 1.1.0.12420 1997-2014 version of software was used.

2.2. Transactivation and NGS

106 fibroblast cells were cultured 24 to 48 hr or until 90% confluent. 2 X
106 cells were treated with either 10 µM all-trans retinoic acid (RA) or an equal
volume of dimethyl sulfoxide (DMSO) for different periods. HeLa S3 were
cultured in RPMI (Thermo Fisher Scientific) media with 10% FBS and 1% penicillin/streptomycin solution. HeLa cell lines were treated with 1 µM RA or an equal
volume of DMSO. The final concentration of DMSO was 0.01% in the cell culture.
The fibroblast cells were harvested with a cell scraper. Each sample was
centrifuged and washed with phosphate buffer saline (PBS) once, centrifuging at
1500 rpm (485 x g) for 5 min at 4 ºC. The pellets were quick-frozen and stored at
-80 ºC. RNA was extracted from pellets using a QIAGEN RNA isolation kit for a
qPCR assay. The qPCR data were analyzed for fold-change in mRNA level of
the human RARB gene at different time points. A time point of maximum
response was determined to prepare the samples for RNA-Seq analysis. Cells
were treated as described above and cell pellets were submitted for Next
Generation sequencing (NGS).
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2.3. RNA Sequencing

Sequencing: The libraries were prepared using the Illumina TruSeq stranded
mRNA kit according to the manufacturer’s protocol, except that the number of
PCR amplification cycles was reduced to 8. The libraries were loaded on cBot
(Illumina, San Diego, CA) at a final concentration of 10 pM to perform cluster
generation, followed by 2 x 76 bp paired end sequencing on a HiSeq 2500
instrument (Illumina). A total of 48 libraries (three biological replicates per
condition) were sequenced in 6 lanes, generating 16-41 million pairs of reads per
sample. Each pair of reads represents a cDNA fragment from the library.

Mapping: The reads were mapped to the human genome (hg19) using TopHat
(version 2.0.10) (105). The overall mapping rate of reads was 87-96%. 76-93%
fragments, depending on the experiment, had both ends mapped to human
genome.

Differential Expression: The number of fragments in each gene from the
RefSeq database (106) (downloaded from UCSC Genome Browser on July 17,
2015) was enumerated using HTSeq-count from the HTSeq software package
(version 0.6.0) (107). Genes with less than 10 fragments in all samples were
removed before differential expression analysis. The differential expression
between conditions was statistically assessed using the R/Bioconductor package
DESeq (version 1.18.0, for DMSO vs. DMSO) (108) and edgeR (version 3.8.6,
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for DMSO vs. RA) (109). Differential expression of genes with FDR (false
discovery rate) ≤ 0.05 was considered significant and a fold change (FC) ≥ 1.5
was used for more rigorous analyses.

2.4. Analysis of NGS data

NGS data were curated to identify the significant (FDR 0.05) differentially
expressed genes in XPA-proficient cells compared to their respective deficient
cells, and genes with fold change levels >1.5. Gene set enrichment analysis,
pathway analysis and statistical gene enrichment analysis were performed using
Gene Ontology (GO) Consortium (110), Gene Set Enrichment Analysis (GSEA)
(111) and QIAGEN’s IPA programs using GO as the data source. Bonferroni’s
correction was used wherever possible when using GO consortium for pathway
and gene enrichment or over-representation test analysis.

2.5. Preparation of components needed to establish the NER dual incision
control assay

2.5.1. M13mp18GTG single stranded DNA

Single stranded circular DNA of M13 bacteriophage (Mp13m18GTG) was
needed to make the double stranded circular DNA containing a cisplatin adduct,
to use as substrate for nucleotide excision repair assays (102). M13mp18GTG
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single stranded circular DNA from M13 bacteriophage was isolated by infecting a
culture of E. coli strain JM109, with the bacteriophage, grown on M9 minimal
selecting media supplemented with 0.1% thiamine. 0.5 ml of bacteriophage stock
(1012 pfu/ml) was incubated at room temperature for 5 minutes in 2.5 ml of fresh
culture of JM109. The mixture was added to 500 ml of Luria Broth (LB) with 5
mM MgCl2 and incubated for 5 hr with vigorous shaking at 37 °C. The culture
broth was centrifuged at 700 x g for 15 minutes to pellet the bacteriophageinfected JM109. Replicative form (RF) of M13mp18GTG, which is a double
stranded circular DNA, was extracted from the pellet. The phage from the
supernatant was precipitated using polyethylene glycol (PEG) and the single
stranded circular DNA was extracted by the phenol chloroform extraction
method. Single stranded DNA was obtained with a concentration of 1.6-2 µg/µl.
The purity of single and double stranded DNA was analyzed on 0.8% agarose
gel run in presence of ethidium bromide at 20 mA for 5 hours (Figure 5).
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SSDNA$ DSDNA$

M13$
SSDNA$
1ug$
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FIGURE 5. Single stranded and double stranded closed circular DNA
derived from M13 bacteriophage

0.8% agarose gel with ethidium bromide (40 µg/ 100 mL) run in Tris-BorateEDTA (TBE) buffer with ethidium bromide at 20 mA for 5 hours. Single stranded
(SSDNA) and double stranded (DSDNA) derived from M13 single stranded DNA
are used as controls to confirm the newly purified single stranded DNA
(M13mp18GTG) as indicated at the top of the gel.
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2.5.2. Whole cell extracts

Whole cell extracts of HeLa S3 and KO38 were prepared following
Biggerstaff and Wood’s protocol (100, 112). A high protein concentration of about
15-20 mg/ml is necessary for the repair assays to take place efficiently in vitro.
The cell extracts are made from 109 cells in 2L or 3L cultures to assure a high
protein concentration. The cells were pelleted and incubated in hypotonic lysis
buffer for 30 min followed by homogenization. Protease inhibitors were added to
inhibit proteolysis. Protein was precipitated and concentrated using sucroseglycerol buffer and ammonium sulfate in 4°C. High-speed centrifugation at
213000 x g at 4°C for 3 hr was done to separate DNA and other impurities from
protein. Supernatant was separated carefully and dialyzed for 8 hr and 2 hr in
dialysis buffer consisting of 0.1 M KCl, 12 mM MgCl2, 1 mM EDTA, 17% glycerol,
2 mM DTT and 25 mM HEPES at pH 7.8. The whole cell extracts were quick
frozen and stored at -80°C in aliquots to avoid repeated freezing and thawing.

2.5.3. Double stranded circular DNA with intrastrand cisplatin adduct

A primer containing a cisplatin adduct for synthesis of double stranded
circular DNA was prepared as described (102). Platination of the 24-mer
oligonucleotide (TCT TCT TCT GTG CAC TCT TCT TCT) was achieved by
incubating a 3:1 molar ratio of oligonucleotide and cisplatin in platination buffer (3
mM NaCl, 0.5 mM Na2HPO4 and 0.5 mM NaH2PO4) for 16 hr. The reaction
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mixture was run on 20% polyacrylamide sequencing gel and gel-purified by the
crush and soak method. In this method, an excised piece of gel is crushed and
soaked in nuclease free water and incubated at 37 °C in a high-speed shaker
(250 rpm). DNA is recovered from the water by removing the gel pieces and then
concentrating DNA in a speed vacuum concentrator. To check if the DNA
obtained was modified or unmodified, DNA samples obtained from the gel
purification were radiolabeled with [γ-32P] deoxyadenosine triphosphates, run on
a 20% polyacrylamide sequencing gel and exposed to X-ray film for 5 minutes.
The unmodified and modified DNA was observed differing in migration by about 1
nucleotide (Figure 6A).

The 24-mer oligonucleotide with a cisplatin adduct was used as primer to
make double stranded circular DNA. The primer (100 µM) was annealed with
single stranded circular DNA derived from M13 bacteriophage (25 µg) in NEB
Buffer 2 in a thermocycler at 65 °C for 5 minutes and gradually cooled to 4°C
over the period of 75 minutes. The complementary strand synthesis was done
using annealed DNA with 8 µg/ml RB69gp43 DNA polymerase in a reaction
mixture containing 3.75 µl NEB buffer 2, 5 mg/ml BSA, 2 mM ATP, 0.6 mM each
dNTP and 30 units of T4 DNA ligase (NEB) in 50 µl volume was done at 37°C for
3 hours. The double stranded DNA so formed was purified by mixing the DNA
with cesium chloride and ethidium bromide and centrifuging for 24 hours at
60,000 rpm in a Type Ti 70 rotor to create a density gradient of cesium chloride
to separate pure double stranded DNA from nicked and linear DNA. The DNA
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bands intercalated with ethidium bromide were identified under UVA light. Double
stranded circular DNA was withdrawn with a syringe and purified from salts and
other impurities by using Amicon 100K centriguation columns (EMD Millipore
Inc.). The substrates were analyzed by restriction digestion with ApaLI enzyme.
Cisplatinated double stranded DNA has a unique digestion site for ApaLI at the
GTG site where cisplatin reacts with the DNA. The cisplatin containing DNA is
resistant to ApaLI while ApaLI cuts the undamaged double stranded DNA (Figure
6B). RB69gp43 was purified by Karen Boulware.
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FIGURE 6. Verification of 1,3 GTG cisplatin primer and the cisplatin adduct
in M13mp18GTG double stranded circular DNA.
A. Denaturing 20% polyacrylamide with radiolabeled 24-mer oligonucleotides
platinated (P), unplatinated (U) and 100 bp DNA ladder (L). B. 0.8% agarose gel
with ethidium bromide run in TBE with ethidium buffer at 20 mM for 8 hours. The
lanes consist of following samples; S: single stranded M13mp18GTG plasmid D:
Double stranded M13mp18GTG.1 and 2: undamaged DNA, 3 and 4: cisplatin
substrate. 1-4 are used in restriction digestion conditions with or without ApaLI.
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2.6. DNA incision and repair assays with cisplatin intrastrand substrate

2.6.1. NER dual incision control assay

Since it is well known that mammalian cells process cisplatin intrastrand
crosslink adduct by NER dual incision (102), we established a control assay
using cisplatin adduct in a circular plasmid. We prepared mammalian whole cell
extracts and a single 1,3 (dGpTpG) cisplatin adduct substrate as described
above and tested in NER dual incision assay using an end-labeling method as
described by Moggs et al., 1996 (102). The 1,3 (dGpTpG) cisplatin substrate was
incubated with mammalian whole cell extracts. Briefly, the reaction mixture
consisted of 50 ng of Pt-GTG or control substrate, 40-45 µg of whole cell extract,
in the NER buffer with a final concentration of 45 mM HEPES-KOH (pH 7.8), 70
mM KCl, 7.5 mM MgCl2, 0.9 mM DTT, 0.4mM EDTA, 2 mM ATP, 2.5 µg of
creatine phosphokinase, 3.4% glycerol and 18 µg of bovine serum albumin in a
10 µl volume. The reaction is incubated at 30 °C for 5 min without DNA and
incubated further for 30 minutes after DNA substrate was added and mixed. An
oligonucleotide with a G-overhang at the 5’ end (GGG GGA AGA GTG CAC AGA
AGA AGA GGC CTG GTC G) was added to the mixture and heated at 95 °C for
5 minutes and cooled gradually at room temperature for 30 minutes. During this
process, the G-overhang oligonucleotide was annealed to a complementary
oligonucleotide excised by dual incision NER. Sequenase polymerase (0.13 U)
was used to add [α-32P] deoxycytidine triphosphates opposite the G-overhang
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using a final concentration of 2 µCi of [α-32P] dCTP and incubated at 37 °C for 3
min followed by addition of 10 µM each of dATP, dTTP and dGTP, and 5 µM
dCTP in the mixture and incubated for 12 more minutes. The reaction was
stopped by adding 90% formamide with bromophenol blue dye and denatured by
heating at 95 °C for 4 minutes. The reaction was run 40 cm on a denaturing 14%
polyacrylamide gel or the sequencing gel at 50°C for about 2 hours or until the
dye ran at the bottom of the gel. The gel was dried for 1-2 hr in gel drier and
exposed to phosphoscreen for 1-2 days.

2.6.2. Primer extension assay to a 1,3 (dGpTpG) cisplatin adduct

A primer extension assay was performed in order to confirm the 1,3
(dGpTpG) cisplatin adduct at a specific site of one strand of the closed circular
double stranded DNA M13mp18GTGX. 25 pmoles of primer
(5’-CAGGAAACAGCTATGAC-3’) was radiolabeled with 17 pmoles of [γ-32P]
ATP at its 5’ end by T4 Polynucleotide kinase (T4 PNK) in 1X T4 PNK buffer for 1
hour at 37 °C. M13mp18GTGX was restriction digested by PvuI restriction
enzyme at 37 °C for 1 hour, heat inactivated, purified by phenol-chloroformisoamyl alcohol and precipitated by 100% ethanol and 3M sodium acetate. 300
ng of purified DNA was incubated with 20 fold more radiolabeled primer at 95 °C
for 4 min, 48°C for 4 min and 37 °C for 1 min in the mixture of Sequenase V2.0
polymerase (USB Inc.) 1.3 U, 1X Sequenase buffer and 80 µM dNTPs mixture, in
a thermocycler. The amount of Sequenase V 2.0, a T7 DNA polymerase, which
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lacks exonuclease activity, was titrated for efficient primer extension. As a control
we used RB69gp43 polymerase, which had worked well in the past for primer
extension of a 30 mer oligonucleotide with its specific primer. Sequenase V 2.0
was found to be working well and we continued to use this polymerase for further
primer extension assays. The reaction was stopped with 90% formamide buffer
and heated at 95 °C for 4 minutes and run in a denaturing 14% polyacrylamide
gel. The gel was dried in heated vacuum gel drier for 30 min to 2 hr. The dried
gel was exposed to phosphoscreen for 1-2 days and scanned in GE Typhoon
FLA 9500.

2.6.3. DNA repair assay

The DNA repair assay was done based on a DNA synthesis reaction as
described in Moggs et al (102). DNA repair assay was performed in similar
reaction conditions as NER dual incision assay in 50 µl volume and it included
radiolabeled with [α-32P] dNTPs (20 mM of each dATP, dTTP, dCTP and dGTP,
2 µCi of 3000 Ci/mmol). 300 ng of DNA was incubated in this reaction for 30 min
at 30 °C after pre-incubating for 5 min without DNA. The repair intermediates
were purified by phenol chloroform isoamyl extraction and ethanol precipitation
as described earlier. The purified DNA is restriction digested with 15 units of
BstN1 in 30 µl volume at 60 °C for 4 hours. The fragments were analysed by
electrophoresis in a denaturing 14% polyacrylamide gel for 1.5 to 2 hr at 50 °C as
described earlier.
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2.7. Construction of TFO-directed psoralen ICL on a a closed circular
double stranded DNA (psoralen-TFO ICL)

2.7.1. Vector with BbsI ends

A pUC19 vector was mutated at T685A by using QuickChange Site-Directed
Mutagenesis Kit (Stratagene), to mutate the Nt.BspQI site. A fragment was
cloned into pCR4-TOPO TA cloning vector (Invitrogen). The mutation was
confirmed by sequencing. The mutated plasmid was transformed into SCS110
Competent Cells (Agilent Technologies) and colonies containing the mutated
plasmid were selected for in LB broth with carbenicillin. DNA was extracted using
a Wizard SV miniprep kit (Promega). Purified mutated-plasmid was restriction
digested with XbaI and KpnI to remove the fragment and an insert consisting of a
TFO binding site and BbsI restriction digestion sites at the ends was ligated with
it. The purified ligated product was transformed in DH5-α cells. Colony PCR was
done to confirm the insertion. Colonies with the correct insertion (result from
PCR) were cultured in LB broth with carbenicillin and DNA was extracted. The
sequences were confirmed for the whole plasmid. Thus this modified pUC19
(pUC19N) consisted of two BbsI sites that brackets a TFO binding site together
with 5’-AT-3’ site for crosslinking with psoralen (113).
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pUC19N (500 µg or more) was restriction digested with BbsI (2 Units/ µg
DNA) at 37 ºC for 16-20 hours. DNA was purified by passing through DNA Clean
& Concentrator centrifugation columns (Zymo Research), run in denaturing 6%
polyacrylamide gel, stained with SYBR Safe (Invitrogen) for 30 min in dark. The
gel was scanned in Typhoon 9500 at 532 nm. The vector bands were marked
and excised with a clean razor blade. The bands were electroeluted in a dialysis
bag in 0.5 X TBE buffer by running the gel at 200 V/cm for 45 minutes. DNA was
precipitated from the electroeluate with 3 M sodium acetate pH 5.2 and ethanol
at -20 ºC overnight, centrifuged at 20,000 x g at 4 ºC for 30 minutes, washed with
2 volumes of 70% ethanol, air dried and resuspended in TE buffer pH 8.0. The
concentration and the purity were measured on a NanoDrop 2000 (Thermo
Scientific).

2.7.2. 50 bp psoralen-TFO ICL

Equal molarity of a 50 bp upper strand oligonucleotide
(5’ PhosCGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC
3’)
and lower strand oligonucleotide (5’PhosGCACGCGTCTTCGAGGGGGAGGGGGTGGTGGGGGGGGAAGGATGAAGAG
C 3’) were annealed together to form a duplex DNA, in TE buffer by heating at 95
ºC for 2 minutes, and gradually letting it cool to room temperature for 3-4 hours
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and stored at 4ºC. 50 fold more psoralen (4’ Hydroxymethyltrixosalen)-TFO (5’
HMT-C6-AGGAAGGGGGGGGTGGTGGGGGAGGGGGA-dGTP-NH2 3’) was
incubated with 50 bp duplex DNA in 5X TBB (triplex binding buffer), which
consisted of 10 mM MgCl2 and 10 mM Tris-Cl pH 7.6 for 16 hours at 37 ºC. The
psoralen-TFO bound to DNA is exposed to UVA (365 nm) at 10 J/m2/s for 30
minutes or 18 kJ/m2. Small amounts of the UVA exposed products were
confirmed for the interstrand crosslink by photo-reversal with UVC (0.7 kJ/m2),
radiolabeled and run in a denaturing 6% polyacrylamide gel. The rest of the UVAexposed products were separated in a denaturing 6% polyacrylamide gel and
stained with SYBR safe (Invitrogen). The interstrand crosslink bands were
excised from the gel making sure not to contaminate them with any monoadducts
or duplex DNA. The gel pieces were crushed in microfuge tubes and soaked in
nuclease free water in a shaker at 37 ºC for 16-20 hours. The water separated
from the gel pieces was collected and filtered through 0.22 µm pore cellulose
centrifugation tubes (Corning® Coaster® SpinX®). It was kept at -80 ºC for 20
minutes and concentrated in a vacuum centrifuge with 37 ºC heat until the
volume reduced to 100-200 µl. The product was purified through a DNA Clean &
Concentration column (Zymo-Research). The purity and the concentration of the
insert were measured on a NanoDrop 2000.
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2.7.3. Ligation reaction

A small-scale ligation reaction was performed with 1:1.5, 1:3, and 1:5 ratio
of vector to insert, 2 units of T4 DNA ligase, 1X T4 ligase buffer, 4 µg of BSA in a
40 µl reaction volume at 16ºC for 2 hours in dark. The reaction was run in a 1%
agarose gel with ethidium bromide. A 1:5 vector to insert reaction was chosen to
scale up the reaction. A large-scale reaction was done in a 20 mL volume (500
X). The reaction was concentrated in Amicon 30K 4 mL centrifugation tubes
(EMD Millipore) at 3452 x g at 4 ºC until the volume was reduced to 1 mL.
Further, the double stranded closed circular DNA was separated from nicked and
single stranded DNA by cesium chloride / ethidium bromide gradient
centrifugation. The double stranded circular DNA is collected from the lower
band. The upper band consists of nicked and single stranded DNA. Ethidium
bromide was removed by several extractions with water-saturated butanol and
butanol is removed by centrifuging it several times with TE in Amicon 10K 4 mL
centrifugation tube (EMD Millipore) at 4 ºC at 800 x g. The solution was
concentrated to a final volume of 250-300 µl. 5X TBB was added to the purified
DNA and incubated at 37 ºC for overnight and stored at 4 ºC.

2.7.4. Confirmation of the ICL in the final product

The final TFO-directed psoralen ICL on a closed circular double stranded
DNA is referred here as psoralen-TFO ICL unless specified. Small amounts of
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the final ICL product (psoralen-TFO ICL) or pUC19N were restriction digested
with BbsI for an hour at 37 ºC and run in a denaturing 6% polyacrylamide gel
along with purified ICL insert, stained with SYBR gold for 30 min in the dark and
scanned in the Typhoon 9500. The restriction digestion of psoralen-TFO ICL
released a 50 bp ICL that runs similar to 50 bp ICL insert whereas the 50 bp
fragment released from pUC19N runs as a normal 50 bp DNA. This confirms that
the final product is TFO directed psoralen interstrand crosslink in closed circular
double stranded DNA.

2.7.5. Plasmid relaxation assay in whole cell extract

500 ng of pUC19N was incubated for 5 minutes to 40 minutes in 100 µg of
HeLa S3 whole cell extract protein or without whole cell extract in ATP
regenerating buffer (NER buffer) as described in the NER incision reactions
above. The reaction was stopped by using 20 mM EDTA and extracted using
RNase, proteinase K, SDS and phenol-chloroform-isoamyl alcohol, and again
with chloroform, precipitated with 100% ethanol and sodium acetate. The DNA
pellet was obtained by high speed centrifugation at 4°C for 30 minutes, washed
with 70% ethanol, air dried and dissolved in 20 µl of TE buffer. The samples were
divided into halves and run in two 1% agarose gels with or ethidium bromide for
either 20 mA for 8 hours or 80V for 2 hours. Pictures were taken in a Bio-Rad
ChemiDoc imager.
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2.8. DNA incision and repair assays with psoralen-TFO ICL

2.8.1. Detection of 3’ incision on the upper and lower strand

50 ng of pso-TFO ICL substrate was incubated in HeLa S3 whole cell
extract in 50 µl reaction volumes in the buffer condition as described in the NER
dual incision control assay. The reaction was stopped by adding 20 mM of EDTA
and purified by equal volume of phenol-chloroform-isoamyl extraction and one
more extraction with chloroform followed by precipitation of intermediate DNA
products with absolute ethanol and sodium acetate by incubating at -20°C for 1
hour. The precipitate was obtained by centrifugation at maximum speed in a
table top centrifuge at 4°C for 30 minutes. The precipitate was washed with 70%
ethanol, air-dried and dissolved in 10 µl TE buffer. The purified DNA products
were restriction digested by 20 units of SbfI (NEB) enzyme for 2 hours at 37 °C
and purified as before and dissolved in 10 µl of TE buffer. A G-overhang labelling
oligonucleotide was designed to detect the incision products on the upper strand.
6 ng of 3’ incision labelling oligonucleotide (5'
GGGGTGCAGGTCGACTCTAGAGCGTCTTCG 3') was added and denatured at
95 °C for 3 minutes and allowed to anneal with the incision products by gradually
cooling at room temperature over 40 minutes. Incorporation of [α-32P]dCTP
complementary to the G-overhangs on the labelling oligonucleotides was done
as described in the NER dual incision control assay. Running the samples in the
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sequencing gel and further processes were done as in the NER dual incision
control assay.

Another G-overhang oligonucleotide
(5'GGGGGAGCACGCGTCTTCGAGGGGGAGGGGGT 3') was used to detect
the incision products at the site within the TFO binding site following the method
described above. For this detection process, the purified DNA product after
incision reaction was restriction digested with 20 units of BfaI (NEB). Similarly to
detect the incision products at the 3’ side on the lower strand, we used a Goverhang oligonucleotide (5' GGGGGTACCGAAGACATCGATGCTCTTCAT 3').

2.8.2. psoralen-TFO ICL repair assays

Repair assays were performed to determine if the psoralen-TFO ICL could
be repaired by human cell extract. The DNA repair synthesis reaction was based
on that described by Moggs et al. (102) and purified as described for the DNA
repair assay above. The purified DNA is restriction digested with 20 units of each
SapI (NEB) and AluI (NEB) at 37 °C in 30 µl volume for 2 hr. The fragments are
analysed by electrophoresis in a denaturing 14 % polyacrylamide gel for 1.5 to 2
hr at 50 °C as described earlier.

A similar repair synthesis assay was also performed where the purified
DNA after the repair reaction was restriction digested by BbsI (NEB).
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Chapter 3. Results - Consequences of XPA disruption in human cells

3.1. Validation of pairs of XPA-deficient and proficient cell lines

The purpose of this study was to determine the extent to which XPA
expression status influences overall gene expression in cultured cells. We
considered it important to use independent, genetically matched pairs of cell lines
where one cell line was completely XPA-deficient, and the other was XPAproficient. Four pairs of cell lines were investigated. Figure 4A indicates the sites
of XPA mutation and deletion in each of the cell lines. Two pairs include widely
used and characterized XPA-deficient cell lines derived from human skin
fibroblasts of individuals with xeroderma pigmentosum group A, XP2OS and
XP12RO. These were compared to the same cell lines complemented with a
plasmid expressing XPA cDNA (Table 1). In both cases, there is ample evidence
that XPA expression fully corrects the UVC radiation sensitivity and NER defect
in these fibroblasts. As another comparison pair of cell lines, two CRISPR-Cas9
mediated XPA-disrupted HeLa S3 cell lines were generated (Figure 4B). We
reasoned that if any XPA-associated gene expression changes were found in
common across several cell lines, they would represent the most biologically
significant consequences of XPA expression.

In three of the XPA mutant cell lines, XPA protein was undetectable by
immunofluorescent staining of cells (Figure 7) or by immunoblotting of cell
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extracts (Figure 8A, B). This is consistent with the known mRNA destabilizing
mutations in XP2OS (114) and XP12RO (115) (Figure 4). The HeLa KO142 cells
encoded an XPA protein with a a deletion of six amino acids (residues 9-14) near
the N-terminus (Figure 4A and 4B). This, perhaps surprisingly, destabilizes XPA
expression, reducing it to ~10% of the level in the HeLa cells (Figure 8A and 8B).
The GTX103168 antibody recognizes the globular core domain of XPA and also
detected a reduced level of XPA in HeLa KO142 cells (Figure 8B). The HeLa
KO38 cells had a frameshift mutation causing early termination and complete
loss of XPA protein. UV irradiation of paired cell lines confirmed the NER
deficiency in the XPA mutant cell lines showing that there is a reduced level of
NER in KO142 (Figure 9A). This is consistent with previous data showing that
XPA levels are rate-limiting for NER when reduced sufficiently (116, 117). HeLa
KO38 cell extracts were completely deficient in NER and could be complemented
by XPA protein (Figure 9B). The common genetic origin of the paired cell lines
was confirmed by short tandem repeat analysis (Table 1). KO38 was a complete
knockout. UV irradiation of paired cell lines confirmed the NER deficiency in the
XPA mutant cell lines showing that there is a reduced level of NER in KO142
(Figure 9A). This is consistent with previous data showing that XPA levels are
rate-limiting for NER when reduced sufficiently (118). We also tested if XPA
protein in KO142 is affected by proteosomal degradation and thus is observed as
low expression. MG132 proteosome inhibitor was used in the cell cultures for 24
hours and cells were subjected to immunoblotting. No difference was observed in
XPA protein level in presence or absence of MG132 (Figure 10). HeLa KO38
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cell extracts were completely deficient in NER and could be complemented by
XPA protein (Figure 9B).

	
  

49

Sample
Name

AMEL

CSF1PO

D16S539

D18S51

D21S11

D3S1358

D5S818

D7S820

XP12RO

X,Y

12

9,11

13,22

30.2

15,16

11,12

12

XPAXP12RO X,Y

12

9,11

13,22

30.2

15,16

11,12

12

XP20S

X

10,11

12

13,16

29,30

16

11

8,12

XPAXP20S

X

10,11

12

13,16

29,30

16

11

8,12

KO142

X

9,10

9,10

16

27,28

15,18

11,12

8,12

KO38

X

9,10

9,10

16

27,28

15,18

11,12

8,12

HeLa S3

X

9,10

9,10

16

27,28

15,18

11,12

8,12

TABLE 1. Short Tandem Repeat (STR) fingerprinting report of cell lines
used in the study
Color-coding is used to denote the XPA proficient cell lines with their deficient
pairs. The scores for repeats of 8 STR fingerprinting markers are given in the
table to show that the cell line pairs matched each other. A total of 14 markers
were used for the STR fingerprinting. All had matching scores for the pairs of cell
lines, showing that the pairs are isogenic.
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DAPI

Anti-XPA (12F5)

Merged

HeLa S3

KO38

KO142

XPA/XP12RO

XP12RO

XPA/XP2OS

XP2OS

FIGURE 7. XPA expression in the cell lines used in this study.

Immunofluorescence images using anti-XPA antibody (12F5) and DAPI showing
the presence of XPA in all XPA-proficient cell lines and little or no XPA in the
deficient cell lines. DAPI (blue) staining of nuclei included for reference.
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A.
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B.

Relative Intensity (%)

100
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Control
XPA
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40
20
0

KO38

KO142
Cell lines

HeLa S3

FIGURE 8. XPA expression in the cell lines used in this study by
immunoblotting.
A. Immunoblot of the cell lines with anti-XPA antibodies CJ1 and GTX103168,
and alpha-tubulin or XPF antibodies as loading controls. B. Quantification of the
immunoblots for the HeLa S3 cell lines shown in (A). The blue bars represent the
alpha-tubulin or XPF control. The red bars represent the anti-XPA antibody.
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A.

100

HeLa S3
XPA KO 38

% Survival

10

XPA KO 142

1
0.1
0.01
0.001
0.0

5.0

10.0

15.0

20.0

25.0

B.

HeLa S3

UVC Dose (J/m2)

- -

+ - - - + + KO38
- 44 88 176 44 88 µg of purified XPA

35 bp
30 bp
25 bp
Lanes 1 2 3 4 5

6

7

FIGURE 9. UVC sensitivity and NER complementation in the cell lines used
in this study.
A. UVC clonogenic survival for XPA-disrupted cell lines KO38 and KO142
compared to wild type HeLa S3. Each point on the survival curves represents the
mean of 3 independent experiments. KO38 is more sensitive to UVC compared
to HeLa S3. KO142 has more moderate sensitivity compared to HeLa S3. B.
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NER complementation assay. KO38 whole cell extracts complemented with
purified XPA protein to produce incision products. 45 µg 1,3-intrastrand
d(GpTpG)-cisplatin substrate was incubated with 45 µg whole cell extract.
Various amounts of purified XPA protein were added to KO38 extracts. NER
activity is detected with 44 and 88 µg of purified XPA combined with KO38
extracts. Incision products were observed as dark bands between 25 bp to 35 bp
where complementation was successful (lanes 6 and 7), similar to the incision
products with NER proficient HeLa S3 extract (lane 1).
UVC sensitivity clonogenic assay was performed by Megan Lowery and Karen
Boulware purified XPA for NER assay.
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Figure 10. Proteasome Inhibition assay
Cells were treated with proteosome inhibitor (MG132) or DMSO for 24 hours.
Cell lysates from the treated cells were immunoblotted to determine if expression
of XPA in KO142 increases in absence of protoesomal degradation. No
difference was observed with and without MG132. XPF was used as a loading
control.
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3.2. XPA is localized in the nucleus of cells and does not require UV
irradiation for import

In order to have a direct role as a transcription factor, XPA would have to
be present in the cell nucleus, where transcription takes place. Although XPA is
localized in the nucleus under standard fixation conditions (Figure 7,11A), we
were concerned about reports that XPA is normally resident in the cytoplasm,
and is only recruited to nuclei following UV radiation exposure (89, 91). We note
that in those studies, cells were first briefly exposed to wash buffers containing
Triton X-100 detergent or the milder fixation agent methanol, or with 0.05% NP40 detergent. As shown in Figure 11A (top row), XPA is entirely resident in the
nucleus as visualized after paraformaldehyde fixation. However, because XPA is
a relatively small protein (31 kDa), it easily leaks out of nuclei into the cytoplasm
after only a few seconds’ exposure to a buffer containing 0.05% NP-40 (Figure
11A, third row).

	
  

56

A

B
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Anti-XPA (12F5)
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_	
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_
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20 J/m2
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60 J/m2

C

DAPI

Anti-XPA

D

Merged

Cells with cytoplasmic XPA ( %)

psoralen
(2 hr)

psoralen
(2.5 hr)

psoralen +
UVA 54 kJ/m2
(2 hr)

Psoralen only
PUVA

100
80
60
40
20
0

36 kJ/m 2

54 kJ/m 2

72 kJ/m 2 126 kJ/m 2

UVA dose

psoralen +
UVA 72 kJ/m2
(2.5 hr)

FIGURE 11. XPA is a nuclear protein and is resistant to extraction from the
nucleus during DNA repair.

A. Immunofluorescence (IF) staining with 12F5 antibody (green) and DAPI (blue).
Cells in the top two panels were stained without exposure to buffer containing
detergent. This shows that XPA is localized in the nuclei of complemented
XPA/XP12RO cells and is absent in XP12RO cells, regardless of exposure to
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UVC. The lower two panels show that brief exposure to a buffer containing 0.05
% NP-40 causes leakage of XPA into the cytoplasm in untreated cells but not in
cells exposed to 20 J/m2 UVC. B. Exposure of XPA/XP12RO cells to increasing
doses of UVC (from 0 J/m² to 60 J/m²) restricts the leakage of XPA to the
cytoplasm. C. XPA/XP12RO cells were exposed to psoralen alone or to psoralen
and then UVA radiation (PUVA). The 2 hr sample received 54 kJ/m² (first dose
18 kJ/m2, second dose 36 kJ/m2) and the 2.5 hr sample received 72 kJ/m² (first
dose 18 kJ/m2, second dose 54 kJ/m2). All cells were exposed briefly to a buffer
containing 0.05 % NP-40 before fixation for IF. XPA leaked to the cytoplasm in
the cells exposed to psoralen alone, but not in the PUVA treated cells. D.
Quantification showing the % of XPA/XP12RO cells with cytoplasmic XPA
following PUVA treatment with increasing total doses of UVA and a constant
concentration of psoralen. All cells were exposed briefly to a buffer containing
0.05 % NP-40 before fixation for IF. The orange bar shows XPA leakage in cells
exposed only to psoralen, and the blue bar shows a reduction in leakage
following DNA damage induction with increasing UVA doses.
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Cells exposed to sufficient DNA damage retained XPA in the nucleus for
at least 30 minutes even after a brief wash in buffer containing NP-40 detergent.
A UVC radiation dose of 20 J/m2 was sufficient to retain all detectable XPA in the
nucleus (Figure 11A, fourth row and Figure 11B). This result is consistent with
previous observations that XPA remains chromatin-bound after UV irradiation,
but is extractable from chromatin in non-damaged cells (119). Similarly, we found
that photoactivated psoralen lesions could also immobilize XPA in the nucleus,
even in cells washed with buffer containing NP-40 (Figure 11C). Consequently,
previous observations suggesting nuclear import of XPA following UV radiation
appear to have been misinterpreted (91). Instead, XPA is always present in
nuclei. Fixation in the presence of detergent facilitates nuclear membrane
permeabilization, and XPA leaks out readily; DNA damage in the nucleus
temporarily restricts such leakage while XPA is engaged in repair. Other
examples of misinterpretation of the subcellular localization of proteins arising
from the presence of detergent have been noted previously (93, 94).

3.3. Influence of XPA status on overall gene transcription

To analyze gene expression, RNA was extracted from a culture of 106
actively growing cells of each pair, and used for next-generation RNA-Seq. To
gauge reproducibility, three replicate cultures were grown independently for each
cell line and RNA was extracted from cell pellets for analysis. With an overall
mapping rate of 87-96%, about 14,000 genes were analyzed for each pair of cell
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lines. With a False Discovery Rate (FDR) less than or equal to 0.05, a very high
proportion of genes (~9000 for each pair) were initially identified as differentially
expressed between paired XPA-proficient and deficient cell lines (Table 2).

However, the expression patterns of these genes for the four pairs of cell
lines were very distinct from one another. The ratio of gene expression was
calculated for XPA+/XPA- for each cell pair; positive log 2 values were termed
“high” and negative log 2 values were termed “low”. We determined the genes
that were uniformly “high” or “low” for all four cell pairs. This narrowed the set to
325 genes with expression that is uniformly influenced by XPA status at an FDR
< 0.05 (Table 2).

This set of 325 genes has the same trend of high or low expression in all
the XPA-proficient cell lines compared to their deficient counterparts (Figure
12A). We used Gene Ontology (GO) consortium software to analyze the
PANTHER pathways of these genes (Table 3). Only 32 of the 325 genes were
assignable by this analysis with p-value less than 0.01, but they represented a
diversity of biological functions (Figure 12B). Notably, a substantial number of
pathways referred to neurological disorders including Alzheimer’s disease,
Huntington’s disease and Parkinson disease.
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Genes

FDR0.05

FC1.5

Cell lines

Analyzed

(High + Low)

(High + Low)

XP2OS vs. XPA/XP2OS

14117

9526

1721 + 2206

XPA/XP12RO

13669

10283

2750 + 2625

KO38 vs. HeLa S3

14564

9520

1769 + 1701

KO142 vs. HeLa S3

13824

8364

1642 + 1422

Common genes

12022

176 + 149

11 + 16

XP12RO vs.

TABLE 2. Summary of genes analyzed by high-throughput RNA sequencing
(RNA-Seq) and significant XPA-related differences.
The first column shows the number of genes analyzable by RNA-Seq for each
XPA proficient / deficient cell pair. The second column shows the number of
genes with differential expression at a False Discovery Rate (FDR) of 0.05. The
ratio of gene expression was calculated for XPA-/XPA+ for each cell pair; positive
ln 2 values are termed “high” and negative ln 2 values are termed “low”. The third
column shows for each cell pair the number of “high” or “low” genes with fold
change (FC) of 1.5 or more.
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+1

A	
  

-1

0

AKR1C2
AKR1C1
MAGEA3
TMPRSS15
NDUFA4L2
AKR1C3
PELI2
WFDC21P
HOMER2
LHX2
DFNB31

CORO6
FCHSD1
PHLDB2
ROR2
SH3RF3
DUSP4
COL1A1
GGT1
PLEKHG5
PPAPDC3
CHCHD10
RCN3
SYNGR1
TBKBP1
PROCR
MMP17
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B	
  
	
  

Total unique genes = 32
5 Integrin signalling pathway (P00034)
5 Wnt signaling pathway (P00057)
5 CCKR signaling map (P06959)
4 Inflammation mediated by chemokine and cytokine signaling pathway (P00031)
4 PDGF signaling pathway (P00047)
4 Oxidative stress response (P00046)
4 Gonadotropin-releasing hormone receptor pathway (P06664)
3 Alzheimer disease-presenilin pathway (P00004)
3 Insulin/IGF pathway-protein kinase B signaling cascade (P00033)
3 T cell activation (P00053)
3 Endothelin signaling pathway (P00019)
3 p38 MAPK pathway (P05918)
2 Apoptosis signaling pathway (P00006)
2 Angiogenesis (P00005)
2 Interleukin signaling pathway (P00036)
2 Ubiquitin proteasome pathway (P00060)
2 Huntington disease (P00029)
2 p53 pathway (P00059)
2 EGF receptor signaling pathway (P00018)
2 Parkinson disease (P00049)
2 PI3 kinase pathway (P00048)
2 Cytoskeletal regulation by Rho GTPase (P00016)
2 Circadian clock system (P00015)
2 B cell activation (P00010)

FIGURE 12. XPA dependent change in gene expression pattern and
biological pathways influenced by XPA status.

A. Heatmap of the 325 genes (Table 2) having the same expression pattern,
either high (yellow) or low (blue) in XPA proficient compared to deficient cell
lines, at a cut off level of FDR 0.05. Differential expression of mRNA was
obtained from high throughput RNA-Seq data. Experiments for each cell line pair
were performed in triplicate and are numbered on the top of the heatmap. The
ratio of gene expression was calculated for XPA-/XPA+ for each cell pair; positive
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log 2 values are termed “high” and negative log 2 values are termed “low”. The
most differentially over- or under- expressed genes are listed to the right. B.
PANTHER pathway analysis was performed using Gene Ontology (GO)
consortium software for the 325 genes shown in part A. Most genes were
unassigned to a pathway by this analysis. The figure shows the pathway
assignment for the subset of 32 genes that had two or more hits to a PANTHER
pathway. The number of genes represented in each pathway is given before the
name of the pathway with PANTHER pathway terms in parenthesis. Some genes
were assigned to multiple pathway terms. The full data and assigned genes are
given in Table 3.
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XPA - vs. XPA+

Panther Pathways

# of
High

Low

genes
hits

BCAR1,
COL1A1,
Integrin signalling pathway (P00034)

PIK3R3,
FLNB
RRAS

5
PPP3CA,

EDN1,
Wnt signaling pathway (P00057)

ITPR1,
FZD1
CHD1L

5

PPP3CA,
RPS6,
CCKR signaling map (P06959)

BCAR1
ITPR1,
PDK1

5

CAMK2D,
Inflammation mediated by chemokine and
RRAS

ITPR1,

cytokine signaling pathway (P00031)
PDK1
MKNK2,

ITPR1,

PIK3R3

PDK1

4

PDGF signaling pathway (P00047)
4

EEF2K,
Oxidative stress response (P00046)

MKNK2
DUSP4,
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4

DUSP1
PPP3CA,
Gonadotropin-releasing hormone receptor
LHX2

ITPR1,

pathway (P06664)
DUSP1
Alzheimer disease-presenilin pathway

4

MMP17,
FZD1

(P00004)

LRP3

Insulin/IGF pathway-protein kinase B

TSC1,

signaling cascade (P00033)

PIK3R3

T cell activation (P00053)

PIK3R3

3

PDK1
3
PPP3CA,
ITPR1

3

EDN1,
Endothelin signaling pathway (P00019)

ITPR1
PIK3R3

3
EEF2K,

p38 MAPK pathway (P05918)

MKNK2
DUSP1

3

RIPK1,
Apoptosis signaling pathway (P00006)
TMBIM6

2

FZD1,
Angiogenesis (P00005)
PIK3R3

2

Interleukin signaling pathway (P00036)

MKNK2

PDK1

2

Ubiquitin proteasome pathway (P00060)

PSMC3

UBE2L6

2

CAPN2,
Huntington disease (P00029)
TUBB2A
p53 pathway (P00059)

	
  

PIK3R3
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2
PDK1

2

p53 pathway feedback loops 2 (P04398)

PIK3R3

PDK1

2

EGF receptor signaling pathway (P00018)

RRAS

PHLDB2

2

Parkinson disease (P00049)

PSMA4

UBE2L6

2

PI3 kinase pathway (P00048)

PIK3R3

PDK1

2

Cytoskeletal regulation by Rho GTPase

TUBB2A,

(P00016)

CFL1

2

PER2,
Circadian clock system (P00015)
PER3

2
PPP3CA,

B cell activation (P00010)

PIK3R3
ITPR1

2

Axon guidance mediated by netrin
PIK3R3
(P00009)

1

Ionotropic glutamate receptor pathway
CAMK2D
(P00037)

1

De novo purine biosynthesis (P02738)

IMPDH2

Coenzyme A biosynthesis (P02736)

PPCDC

1
1

Alpha adrenergic receptor signaling
ITPR1
pathway (P00002)

1

Hypoxia response via HIF activation
PIK3R3
(P00030)

1

Nicotine pharmacodynamics pathway
PPP1CA
(P06587)

1

Ascorbate degradation (P02729)
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1

Heterotrimeric G-protein signaling pathwayGq alpha and Go alpha mediated pathway

ITPR1

(P00027)

1

p53 pathway by glucose deprivation
TSC1
(P04397)

1

mRNA splicing (P00058)

PRPF19

1

Heterotrimeric G-protein signaling pathwayGi alpha and Gs alpha mediated pathway

PHKA1

(P00026)

1

Vitamin D metabolism and pathway
RXRA
(P04396)

1

VEGF signaling pathway (P00056)

PIK3R3

1

Transcription regulation by bZIP
TTF1
transcription factor (P00055)

1

General transcription regulation (P00023)

TTF1

Ras Pathway (P04393)

1
PDK1

1

General transcription by RNA polymerase I
TTF1
(P00022)

1

FGF signaling pathway (P00021)

PPP4R1

1

TGF-beta signaling pathway (P00052)

RRAS

1

FAS signaling pathway (P00020)

LMNA

1

Thiamin metabolism (P02780)

ITPA

1

Histidine biosynthesis (P02747)
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1

Histamine H1 receptor mediated signaling
ITPR1
pathway (P04385)

1

Heme biosynthesis (P02746)

RSAD1

Cadherin signaling pathway (P00012)

FZD1

Blood coagulation (P00011)

1
1

PROCR

1

Dopamine receptor mediated signaling
PPP1CA
pathway (P05912)

1

Muscarinic acetylcholine receptor 1 and 3
ITPR1
signaling pathway (P00042)

1

Formyltetrahydroformate biosynthesis
DHFR
(P02743)

1

Angiotensin II-stimulated signaling through
ITPR1
G proteins and beta-arrestin (P05911)

1

Tetrahydrofolate biosynthesis (P02742)

DHFR

1

Metabotropic glutamate receptor group I
ITPR1
pathway (P00041)

1

De novo pyrimidine ribonucleotides
CTPS2
biosythesis (P02740)

	
  

1

69

TABLE 3. Panther pathways created using Gene Ontology (GO) database
for common genes with similar expression pattern at FDR0.05 in XPA- vs.
XPA+ comparison in all four pairs of cell lines used in the study.
The first column consists of the Panther pathways for common differentially
expressed genes. Columns on the right consist of the common higher or lower
expressed genes for each pathway, and the total number of gene hits observed
for each pathway. The pathways for neurological functions are presented in bold.
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Fold enrichment
GO terms for FC2
genes overlaping
with 'Mitochondria’
(A)

KO142 vs.

KO38 vs.

XP12RO vs.

XP2OS vs.

HeLa S3

HeLa S3

XPA/XP12RO

XPA/XP2OS

or ‘Mitophagy’ (B) GO
genes

A

B

A

B

A

B

A

B

27.01

> 100

21.43

> 100

24.6

> 100

28.43

> 100

27.01

> 100

21.43

> 100

24.6

> 100

28.43

> 100

27.01

> 100

21.43

> 100

24.6

> 100

28.43

> 100

21.77

> 100

17.27

> 100

19.83

98.69

24.67

> 100

21.77

> 100

17.27

> 100

19.83

98.69

24.67

> 100

19.48

> 100

15.45

95.33

17.74

88.3

22.08

94.61

13.66

33.18

11.28

28.66

11.26

26.55

15.17

28.44

response to
mitochondrial
depolarisation
(GO:0098780)
mitophagy in response
to mitochondrial
depolarization
(GO:0098779)
macromitophagy
(GO:0000423)
mitophagy
(GO:0000422)
mitochondrion
disassembly
(GO:0061726)
organelle disassembly
(GO:1903008)
mitochondrion
organization
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(GO:0007005)
macroautophagy
15.53

70.41

10.56

68.58

12.12

60.35

15.09

64.66

12.43

52.83

8.45

48.02

8.96

42.26

12.07

45.28

8.66

-

8.09

-

6.57

-

6.83

-

6.57

-

5.46

-

5.1

-

6.03

-

6.55

-

5.45

-

5.31

-

5.31

-

23.91

-

29.26

-

21.77

-

25.55

-

20.42

-

21.54

-

23.86

-

(GO:0016236)
autophagy
(GO:0006914)
regulation of cellular
protein localization
(GO:1903827)
regulation of
establishment of
protein localization
(GO:0070201)
regulation of cellular
localization
(GO:0060341)
regulation of
establishment of
protein localization to
mitochondrion
(GO:1903747)
regulation of
mitochondrion
19.11
organization
(GO:0010821)

-

xenophagy
> 100
(GO:0098792)

-

regulation of immune

-

	
  

68.79
-

26.13

-

72

86.48
-

15.59

-

92.66
-

24.5

-

28

effector process
(GO:0002697)
single-organism
organelle organization
(GO:1902589)

14.02
-

12.11
-

11.21
-

12.02
-

cellular response to
12.09
stress (GO:0033554)

-

12.36
-

10.36
-

11.1
-

TABLE 4. Gene Ontology (GO) terms for genes for ‘Mitophagy’ or
‘Mitochondria’ overlapping with 2 fold or more changed (FC2) genes in
XPA- vs. XPA+ comparison in all four cell lines.
The first column consists of the GO terms related to ‘Mitochondria’ or ‘Mitophagy’
from GO database. In the table, ‘A’ represents ‘Mitochondria’ and ‘B’ represents
‘Mitophagy’. Each column ‘A’ and ‘B’ shows the fold enrichment of FC2 genes for
each cell line pairs in the GO terms listed in the first column.
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Biological

Genes with

Functions

FC >1.5

Gene Name

XP12RO

XP2OS

KO38

vs.

vs.

vs.

KO142

XPA/XPA

XPA/XP

HeLa

vs.

12RO

2OS

S3

HeLa S3

Fold

Fold

Fold

Fold

Change

Change

Change

Change

16

48

7

7.5

21

20

17

7.5

12

14

2

955

16

11

4

52

4

6.9

1.9

2

1.5

2.63

7.5

7

Aldo-Keto
Reductase Family
Metabolism

AKR1C1

1, Member C1
Aldo-Keto
Reductase Family

Metabolism

AKR1C2

1, Member C2
Transmembrane
Protease, Serine

Metabolism

TMPRSS15

15
Melanoma-

Unknown in
normal cells

Associated Antigen
MAGEA3

3
Aldo-Keto
Reductase Family

Metabolism

AKR1C3

1, Member C3
NADH

Mitochondrial

Dehydrogenase

function

(Ubiquinone) 1

(ATP

Alpha

generation)
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Subcomplex, 4-
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Like 2
Pellino E3
Ubiquitin Protein
Ligase Family
Immunity

PELI2

Member 2

1.7

2.6

1.5

5.5

1.8

2.5

1.8

1.5

6.2

2

1.9

11

9

1.9

1.9

1.4

1.5

1.9

1.7

1.6

-21

-1782

-6.5

-2

-2.4

-84.4

-1.6

-6.4

-9.8

-42

-1.5

-1.7

WAP FourDisulfide Core
Neurological
development

Domain 21,
WFDC21P

Pseudogene
Homer, Neuronal

Circadian
entrainment

Immediate Early
HOMER2

Neural crest
development

Gene, 2
LIM Homeobox

LHX2

Protein 2
Deafness,

Auditory
maintenance

Autosomal
DFNB31

Recessive 31
Receptor Tyrosine

GPCR
pathway

Kinase Like
ROR2

Orphan Receptor 2
SH3 Domain
Containing Ring

Not clear

SH3RF3

Finger 3
Coiled-Coil-HelixCoiled-Coil-Helix

Mitochondrial
organization

	
  

Domain Containing
CHCHD10

10

75

Actin binding

CORO6

Coronin 6

-1.5

-32

-1.7

-1.7

RCN3

Reticulocalbin 3

-3.2

-21

-1.5

-1.5

-274

-16

-3

-3.6

-4.3

-6.5

-1.5

-4

-2.5

-3.5

-1.7

-1.5

-1.5

-2.5

-1.5

-2

-1.9

-1.6

-1.4

-1.9

Calcium ion
binding
Negative
regulation of
myoblast

Phospholipid
PPAPDC3

Phosphatase 7

Negative
regulation of
MAPK

Dual Specificity
DUSP4

Phosphatase 4
FCH And Double

Not clear

FCHSD1

SH3 Domains 1
Collagen Type I

Collagen

COL1A1

Alpha 1
GammaGlutamyltransferas

Not clear

GGT1

e1
TBK1 Binding

TNF pathway

TBKBP1

Protein 1

-3.7

-1.6

-2.1

-2.1

Not clear

SYNGR1

Synaptogyrin 1

-1.9

-1.6

-2

-2.5

-1.7

-1.6

-9

-2.3

Matrix

Matrix

metalloprotea

Metallopeptidase

se activity

MMP17

17
Breast Carcinoma
Amplified

Breast cancer

BCAS4

Sequence 4

-2

-1.5

-2.8

-2

PROCR

Protein C Receptor

-2

-1.5

-3.4

-1.5

Platelate
activation
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Pleckstrin
Homology Like
Domain Family B
Cytoskeleton

PHLDB2

Member 2

-1.5

-1.5

-1.5

-1.5

Table 5. Common genes that are the most differentially expressed in all
four pairs of cell lines.
Table includes the major biological functions in the first column for the gene list
given in the second column. The names of the genes are given in the third
column. The left four columns are the fold change of the differential expression in
four pairs of cell lines in XPA- vs. XPA+ comparison. The positive fold change
indicates the higher expression whereas the negative fold change indicates the
lower expression in XPA+ compared to XPA-. Genes with positive fold change
are given in bold letters.
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3.4. XPA status influences expression of genes affecting mitochondria and
mitophagy

Because XPA status has been reported to affect mitochondrial function
and mitophagy, we examined gene expression specifically in relevant pathways.
To narrow down the analysis, we focused on genes with a fold change (FC) of
1.5 or more in each pair of cell lines (Table 2). Genes listed on the GO
consortium for ‘mitophagy’ or ‘mitochondria’ were overlapped with FC2 genes
from our experiment. Significantly, the FC2 genes with XPA-dependent changes
common to all four cell lines were highly enriched for GO terms related to
mitophagy or mitochondria (Table 4). This confirms and extends the evidence for
an influence of XPA status on gene expression affecting mitochondrial
maintenance and regulation of mitophagy.

3.5. Classification of the most differentially expressed genes common
among all cell pairs

To determine which genes have expression most reproducibly affected by
XPA status, we began with the group with at least a 1.5 fold change (FC1.5) in
each cell pair. The overlaps in the gene list between these four sets were
determined. This narrowed the set to only 27 genes that were differentially
expressed at FC1.5 and have a uniform trend of high or low expression among
all four pairs of cell lines (Table 5). Among the most differentially expressed
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genes were AKR1C1, AKR1C2, and AKR1C3. These genes are adjacent on
human chromosome 10p15-p14 and encode (Figure 13) members of the
aldo/keto reductase superfamily, discussed further below. There were other AKR
family genes also close to these three genes (AKR1E2 and AKR1C4), which
were not differentially expressed in XPA- vs. XPA+ analysis. It is possible that
there are common regulatory factors for these three genes. Another gene more
highly expressed in XPA+ cells was NDUFA4L2, which encodes a subunit of an
NADH dehydrogenase localized in the mitochondria and important for ATP
generation. Other significant “high” genes were WFDC21P, HOMER2, LHX2 and
DFNB31, which have neurological functions (Table 5).

We analyzed the AKR1C proteins in the cell pairs by immunoblotting. Both
AKR1C1 and AKR1C2 protein levels were significantly lower in all XPA- cells
compared to XPA+ cells (Figure14A and 14B). AKR1C3 protein levels were
slightly higher in HeLa S3 than in the XPA mutants, and absent in some of the
fibroblast XPA- and XPA+ cell lines (Figure 14B).
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FIGURE 13. Location of AKR1C1, AKR1C2 and AKR1C3 on human
chromosome 10.

AKR1C1, AKR1C2 and AKR1C3 are located adjacent to one another and with
other AKR family genes; AKR1E2 and AKR1C4. AKR1C1 and AKR1C3 have
same direction of expression whereas AKR1C2 has opposite direction. Histone
modifications indicate there may be common regulatory factors for AKR1C1,
AKR1C2 and AKR1C3 genes. Different length of the genes represents different
variants.
The figure is adapted from the UCSC Genome Browser on Human (Dec. 2013
hg38 Assembly) or Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH,
Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res.
2002 Jun;12 (6):996-1006.
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KO38

HeLa S3

KO142

XPA/XP12RO

XP12RO

XP2OS

XPA/XP2OS

A.

XPF
AKR1C1

XPF
AKR1C2

XPF

*
AKR1C3

B.
120
100

XPF
AKR1C1
AKR1C2

80
60
40
20

Cell	
  lines

H
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a
A
/X S3
P1
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2
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S
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O
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O
1
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R
XP O
2O
S
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a
A
/X S3
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S
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O
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O
14
XP 2
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Relative intensity of protein bands ( %)

* Non-specific band

FIGURE 14. Analysis of the most drastically changed gene expressions in
XPA proficient compared to the deficient cell lines.
A. Immunoblot for the most differentially high expressed genes (AKR1C1,
AKR1C2 and AKR1C3) in XPA proficient compared to deficient cell lines.
AKR1C1 and AKR1C2 protein levels were lower in XPA deficient cells compared
to proficient cells whereas AKR1C3 protein level was inconclusive. B.
Quantification of band intensity of AKR1C1 (red) and AKR1C2 (orange) and XPF
(blue) as loading control.
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KO38

KO142 vs.

common

XP2OS vs.

XP12RO vs.

common in

vs.

HeLa S3

in both

XPA/XP2OS

XPA/XP12RO

both fibroblast

HeLa

HeLa

S3

pairs

pairs

High

1311

1184

458

1380

2409

341

Low

1355

1076

346

1744

2163

462

Total

2666

2260

804

3124

4572

803

TABLE 6. More commonalities when fibroblasts and HeLa cells are
considered independently.
Number of genes with FC1.5 or more in XPA- vs. XPA+ comparison in fibroblast
cell lines or HeLa cell lines shows more common high or low expression patterns
compared to commonality among all four cell lines.
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3.6. More commonalities within fibroblast and HeLa cell pairs

We also analyzed the data to compare the two skin fibroblast pairs to one
another (XP12RO and XP2OS) and the two sets of data derived from HeLa cell
(KO38 pair and KO142 pair). Within these pairs, there were many more genes in
common that were differentially expressed in an XPA-dependent manner (Table
6). For FC1.5 genes, 803 (341 high + 462 low) genes in fibroblast cell lines and
804 (458 high + 346 low) genes in HeLa knockout cell lines had a similar
expression pattern, in contrast to the only 27 genes common between all four cell
lines at this expression level. These genes were overrepresented for pathways
similar to those observed with all four pairs of cell lines with more number of
genes (Table 7) and some pathways with less number of genes and are different
in fibroblasts and HeLa are listed in Table 8.

3.7. Retinoic acid transactivation affects XPA-dependent transcription
related functions

Because retinoic acid transactivation of some genes has been shown to
depend on NER components in some instances, we treated cell pairs with alltrans retinoic acid (RA) or a DMSO control. Quantitative PCR was used to
assess the response of retinoic acid treatment to the cell lines. All cell lines, both
XPA-proficient and deficient, responded to RA as shown by an increase in the
mRNA level of RARB, a direct target gene of RA (Figure 15A). HeLa cell lines
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had the lowest transcriptional response of RARB. RNA-sequencing data from
cells treated with retinoic acid or DMSO for 7 hr were analyzed for biological
functions by Ingenuity Pathway Analysis (IPA). IPA analysis was done for the
significantly differentially expressed genes (FDR0.05) for DMSO vs. RA, for
genes with higher expression in XPA-proficient cell lines compared to their
respective XPA-deficient cell lines. This showed that the XPA-dependent RA
response is enriched for transcription related biological functions (Figure 15B).
Transcription related functions had the highest rank on the list of the –log (pvalue) compared to other biological functions. Thus for retinoic acid
transactivation, XPA proficiency might be functionally important. However, we
found no common gene expression pattern among all four pairs of cell lines.
There were 18 common genes that were FC1.5 or more changed within RA
treated HeLa S3 compared to KO38 or KO142. However, no common genes
were found in skin fibroblasts in similar conditions. As each cell line responded to
retinoic acid treatment in a different manner, it appears that the gene expression
changes are also different in different cell lines. Nevertheless, although specific
gene expression patterns were different in all four sets of cell lines, common
biological functions were represented by the gene expression changes in each
pair of cell lines, with transcriptional functions at the top of the list (Figure 15B).
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XPA - vs. XPA+
# gene hits in

# of gene hits

PANTHER pathways

GO term

HeLa cells

in Fibroblasts

Wnt signaling pathway

(P00057)

21

9

Huntington disease

(P00029)

14

6

Cadherin signaling pathway

(P00012)

14

9

Integrin signaling pathway

(P00034)

13

12

signaling pathway

(P00031)

13

8

CCKR signaling map

(P06959)

12

9

hormone receptor pathway

(P06664)

11

17

PDGF signaling pathway

(P00047)

10

6

pathway

(P00018)

10

10

Angiogenesis

(P00005)

9

7

(P00004)

9

10

receptor signaling pathway

(P00044)

9

2

Cytoskeletal regulation by

(P00016)

9

3

Inflammation mediated by
chemokine and cytokine

Gonadotropin-releasing

EGF receptor signaling

Alzheimer disease-presenilin
pathway
Nicotinic acetylcholine
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Rho GTPase
Apoptosis signaling pathway

(P00006)

7

4

Parkinson disease

(P00049)

7

2

Interleukin signaling pathway

(P00036)

7

6

FGF signaling pathway

(P00021)

7

6

Blood coagulation

(P00011)

7

2

pathway

(P00026)

6

11

Endothelin signaling pathway

(P00019)

6

7

secretase pathway

(P00003)

5

5

p53 pathway

(P00059)

5

4

T cell activation

(P00053)

5

3

TGF-beta signaling pathway

(P00052)

5

7

Oxidative stress response

(P00046)

5

5

activation

(P00030)

4

1

Ras Pathway

(P04393)

4

6

(P00027)

4

6

Heterotrimeric G-protein
signaling pathway-Gi alpha
and Gs alpha mediated

Alzheimer disease-amyloid

Hypoxia response via HIF

Heterotrimeric G-protein
signaling pathway-Gq alpha
and Go alpha mediated
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pathway
B cell activation

(P00010)

4

3

(P04374)

4

1

netrin

(P00009)

3

1

VEGF signaling pathway

(P00056)

3

3

PI3 kinase pathway

(P00048)

3

1

(P00033)

3

1

signaling pathway

(P04391)

3

1

p38 MAPK pathway

(P05918)

3

2

pathway

(P00054)

2

6

Notch signaling pathway

(P00045)

2

3

(P04373)

2

3

(P00043)

1

3

(P05917)

1

3

5HT2 type receptor mediated
signaling pathway
Axon guidance mediated by

Insulin/IGF pathway-protein
kinase B signaling cascade
Oxytocin receptor mediated

Toll receptor signaling

5HT1 type receptor mediated
signaling pathway
Muscarinic acetylcholine
receptor 2 and 4 signaling
pathway
Opioid proopiomelanocortin
pathway
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TABLE 7. Cell specific analysis of biological pathways with more number of
genes represented in each pathway compared to analysis with all cell lines.
PANTHER pathways significantly represented by common differentially
expressed genes (FC=>1.5) in XPA proficient cells compared to XPA deficient
cells among HeLa cells or fibroblast cells. Table consists of the list of the
pathways that are common in both among HeLa cells (KO38 vs. HeLa S3 and
KO142 vs. HeLa S3) and fibroblasts (XP12RO vs. XPA/XP12RO and XP2OS vs.
XPA/XP2OS) excluding the pathways that consists of only one or two genes in
both groups.
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XPA- vs. XPA+
# Gene hits in

# Gene hits

Fibroblasts

in HeLa cells

PANTHER pathways

GO term

GABA-B receptor II signaling

(P05731)

4

0

Opioid prodynorphin pathway

(P05916)

3

0

FAS signaling pathway

(P00020)

3

0

signaling pathway

(P00002)

2

0

Enkephalin release

(P05913)

2

0

signaling pathway

(P04379)

2

0

5-Hydroxytryptamine degradation

(P04372)

2

0

semaphorins

(P00007)

1

0

O-antigen biosynthesis

(P02757)

1

0

N-acetylglucosamine metabolism

(P02756)

1

0

biosynthesis

(P00001)

1

0

Methionine biosynthesis

(P02753)

1

0

Lipoate_biosynthesis

(P02750)

1

0

Glutamine glutamate conversion

(P02745)

1

0

Coenzyme A biosynthesis

(P02736)

1

0

Alpha adrenergic receptor

Beta3 adrenergic receptor

Axon guidance mediated by

Adrenaline and noradrenaline
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Synaptic vesicle trafficking

(P05734)

1

0

(P05730)

1

0

(P04386)

1

0

receptor signaling pathway

(P04380)

1

0

Proline biosynthesis

(P02768)

1

0

Glycolysis

(P00024)

0

3

Pentose phosphate pathway

(P02762)

0

3

mRNA splicing

(P00058)

0

2

(P00055)

0

2

(P06587)

0

2

ribonucleotides

(P02775)

0

2

Cell cycle

(P00013)

0

2

biosynthesis

(P02727)

0

1

JAK/STAT signaling pathway

(P00038)

0

1

(P00035)

0

1

Endogenous cannabinoid
signaling
Histamine H2 receptor mediated
signaling pathway
Corticotrophin releasing factor

Transcription regulation by bZIP
transcription factor
Nicotine pharmacodynamics
pathway
Salvage pyrimidine

Androgen/estrogen/progesterone

Interferon-gamma signaling
pathway
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p53 pathway by glucose
deprivation

(P04397)

0

1

(P00028)

0

1

(P00022)

0

1

(P02774)

0

1

(P05911)

0

1

signaling pathway

(P04385)

0

1

Pyrimidine Metabolism

(P02771)

0

1

Purine metabolism

(P02769)

0

1

Heterotrimeric G-protein signaling
pathway-rod outer segment
phototransduction
General transcription by RNA
polymerase I
Salvage pyrimidine
deoxyribonucleotides
Angiotensin II-stimulated signaling
through G proteins and betaarrestin
Histamine H1 receptor mediated

TABLE 8. Cell specific analysis of biological pathways showing difference
in HeLa and fibroblasts.
PANTHER pathways significantly represented by common differentially
expressed genes (FC=>1.5) in XPA proficient cells compared to XPA deficient
cells among HeLa cells or fibroblast cells. Table consists of the list of the
pathways that are different in in HeLa cells (KO38 vs. HeLa S3 and KO142 vs.
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HeLa S3) and fibroblasts (XP12RO vs. XPA/XP12RO and XP2OS vs.
XPA/XP2OS).

	
  

92

Average -log(p-value) 4 pairs of cell lines

B.

	
  
0

Functions

transcription
expression of RNA
transcription of RNA
phosphorylation of protein
transcription of DNA
cell death
apoptosis
proliferation of cells
activation of DNA endogenous promoter
ubiquitination of protein
cell cycle progression
organization of cytoskeleton
protein kinase cascade
cell movement
migration of cells
arrest in cell cycle progression
organization of actin cytoskeleton
metabolism of protein
phosphorylation of L-amino acid
transport of lipid
communication
angiogenesis
phosphorylation of L-tyrosine
transport of cholesterol
communication of cells
healing of wound
MAPKKK cascade
homeostasis of cholesterol
coagulation of blood
signal transduction
differentiation of cells
aggregation of blood platelets
activation of Protein kinase
formation of focal adhesions
fatty acid metabolism
autophosphorylation of protein

K

a

O

eL
S3

14
2
XP KO
A
/X 38
P2
O
XP XP S
2
A
/X OS
P1
2
XP RO
12
R
O

H

mRNA fold change

A.
20
18
16
14
12
10
8
6
4
2
0

XPA+
XPA-

Cell lines treated with DMSO vs RA

Functional analysis of differential expression of DMSO vs. RA

15

10

XPA status
XPAXPA+

5

FIGURE 15. Retinoic acid transactivation affects XPA-dependent

transcription related functions.
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A. qPCR results for all the XPA proficient and deficient cell lines showing
responses to RA treatment at 7 hours. RARB gene expression was analyzed for
RA or DMSO treated cell lines. GAPDH was used as control. The mRNA of
RARB in RA treated condition was normalized to the DMSO- only controls. B.
IPA analysis comparing the RA treated to untreated cells. Genes that were
differentially expressed at FDR0.05. XPA proficient cell lines (red) compared to
the XPA deficient cell lines (black) were analyzed. The scores are presented as
negative log values of p-values, showing that XPA+ cells have higher significant
differences than in XPA- cells, comparing the response to RA treatment with
control treatment for a given function shown on the x-axis.
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Chapter 4. Results - Processing of a TFO-directed interstrand crosslink in
human cell extracts

ICL causing agents are used in chemotherapies to kill cancer cells but the
exact mechanism for the processing DNA ICLs in human cells is not known. This
project explored the mechanism of processing DNA-ICLs in human cells. For this
purpose we first established a control NER dual incision assay with a 1,3
d[GpTpG] cisplatin intrastrand crosslink built into a closed circular double
stranded M13mp18GTGX DNA (102). The substrate was confirmed, and cell
extracts and the reaction conditions were established to show the control assay
works well for the incision and repair assays. To map out the incision sites on the
psoralen-TFO ICL substrate we constructed a site-specific psoralen ICL in a
closed circular DNA with a psoralen conjugated to a TFO. We used this substrate
in the incision and repair assays to study the processing in human cell extracts.

4.1. Validation of the cisplatin intrastrand substrate by primer extension
assay

The purified cisplatin intrastrand crosslink was used in a primer extension
assay to detect blockage of the extension of DNA polymerase. The lesion
successfully blocked the extension process of the Sequenase polymerase
(Figure 16). A PvuI restriction digested fragment encompasses the cisplatin
intrastrand adduct. The fragment is 201 bp long with a primer-annealing site at
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one end. The adduct is 39 nucleotides away from the 5’ end of the primer. As
expected, we observed that the restriction digested fragment extended to 201 bp
when no adduct is present and the adduct-obstructed fragment extended to only
39 bp, confirming the presence of the cisplatin adduct at the specific site.

We used two kinds of controls. One is the replicative form of the M13
single stranded plasmid, which is a double stranded circular DNA. The other
control plasmid was made similar to the cisplatin-damaged plasmid, except an
unplatinated oligonucleotide was used instead of cisplatin containing
oligonucleotide. In both controls there was full extension of the radiolabelled
primer to 201 bp. Some extended 201 bp fragments were also observed with
damaged plasmid. This may be due the presence of small amount of
unplatinated plasmid.
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Pt
RF
Con

330 bp
201 bp

100 bp
60 bp

201 bp!

50 bp
39 bp

39 bp!

Pvu!I!cut!fragment!of!M13mp18GTGX!
17 mer radiolabeled primer!

40 bp
30 bp

20 bp

FIGURE 16. Primer extension assay using a fragment of M13mp18GTGX
from the 5’ end of the radiolabelled primer to the 3’ end cut by PvuI enzyme.

This fragment is 201 bp long. Denaturing 14 % polyacrylamide gel showing
control (con) and replicative form of M13mp18GTG (RF) extended to 201 bp and
cisplatin substrate (Pt) blocked by the adduct at 39 bp.
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4.2. NER dual incision control assay was established

4.2.1. Major incision products and minor incision products were observed
as shown by previous studies

A 1,3d[GpTpG] cisplatin intrastrand crosslink built into a closed circular
double strand M13mp18GTGX DNA has been shown to be processed by human
cell extracts in NER dependent dual incision (102). It has been reported that
human cell extracts make major incisions between the 8th and 9th nucleotide at
the 3’ side and between the 15th and 16th nucleotide at the 5’ side, resulting in the
major incision products of this cisplatin adducts in human cells of 27-32
nucleotide long (102). This substrate was used as a control for the psoralen
interstrand crosslink substrate. Using the similar conditions of reactions that were
used in Moggs et al, 1998 (102), we performed a dual incision assay and
mapped the incision product by using the G-overhang oligonucleotide labelling
method. We successfully detected incision products that were produced due to
dual incision on either side of the cisplatin adduct using human cell extracts. The
incision products produced were between 25 to 35 nucleotides long (Figure 17).
The major incision products were observed between 27-29 nucleotides long. The
dual incision result in Mogg’s et al, 1998 (102), where the incisions were 15
nucleotides away from the adduct at the 5’ side and 9 nucleotides away from the
adduct on the 3’ side was reproduced in our dual incision assay. This result
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confirmed that the cell extract, the DNA substrate, and the reaction conditions we
used are all functional for the incision reactions.
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A.

B.

FIGURE 17. NER dual incision control-assay.
A. Detection of incision products by the G-overhang end labeling method, which
adds 4 nt to the primary incision product length as described in the Chapter 2. B.
Denaturing 14% polyacrylamide sequencing gel with major and minor incision
products plus 4 radiolabelled CTPs, indicated by long and short arrows
respectively, from NER dual incision control assay. The major labeled products of
30, 33 and 34 nt correspond to the major primary incision products of 26, 29 and
30 nt as observed previously (102).
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4.2.2. A 1,3 d[GpTpG] cisplatin intrastrand crosslink is repaired by HeLa
whole cell extract as observed by previous studies

We wanted to confirm that the reaction conditions that we have
established can be used for repair synthesis with the cisplatin substrate, as it is
known that this substrate can be repaired well in human cell extracts provided
with the supply of necessary dNTPs. We performed the repair synthesis assay
with similar reaction conditions as in the Moggs et al., 1996 paper (102). HeLa
S3 cell extracts can repair the cisplatin substrate by filling the gap created by
dual incision with radiolabelled dNTPs. Then, the plasmid was digested with
BstN1, which creates 8 different size fragments in M13mp18GTGX DNA, among
which a 33 bp fragment is where the repair synthesis occurs. We observed this
fragment with the highest intensity by autoradiography (Figure 18). Some
neighbouring fragments were also labelled. These fragments were fainter than 33
bp fragments indicating that the more radiolabelled dNTPs preferentially were
incorporated into the 33 bp region. This result suggests that the repair process
has occurred, which assured us that we could use this assay to study the repair
of TFO-directed ICL substrate.

4.2.3. Incisions on the 1,3 d[GpTpG] cisplatin intrastrand crosslink were
dependent on NER protein

Dual incision of the cisplatin substrate is mediated by NER (102). An XPA
deficient HeLa S3 (KO38) was made by CRISPR-Cas9 technology. We prepared
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the KO38 whole cell extracts and used purified XPA protein to complement the
deficiency in the dual incision assay. We observed the similar dual incision
products as with XPA proficient HeLa S3 whole cell extract in the complemented
assay. No products were detected in KO38 whole cell extract without
complementation, showing that the incisions are dependent on NER. The result
is presented in Section 3.1 and Figure 9B.
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Control

Pt

A.

B.

127	
  bp
BstN1

68	
  bp

100 bp

BstN1

	
  

Pt

50 bp

33	
  bp

BstN1
38	
  bp

35 bp

BstN1

30 bp

57	
  bp
25 bp

BstN1

15 bp

FIGURE 18. Repair synthesis assay.
A. Denaturing 14% polyacrylamide gel showing BstN1 digested fragments of
cisplatin and control substrate after repair synthesis. A 33 bp long band
encompassing the cisplatin substrate was most intense compared to the control,
showing incorporation of radiolabelled dNTPs at the repair site. B. Schematic
diagram of restriction digestion sites around cisplatin adduct.
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4.3. TFO-directed Psoralen interstrand crosslink was constructed and
purified

The TFO –directed psoralen interstrand crosslink in a closed circular
double stranded DNA was constructed, purified and used as an ICL substrate in
the experiments to determine how it is processed by mammalian cells.
Construction of pure and high yield ICL substrate has been difficult task for ICL
repair studies. The 50 bp short duplex TFO-directed psoralen ICL substrate was
made using technology and reagents developed by Dr. Karen Vasquez’s
laboratory (25). Then we developed the methodology to construct TFO- directed
psoralen ICL in closed circular DNA (Figure 19, see methods in Chapter 2 for
details). Confirmation of the components of the TFO-psoralen ICL is presented in
the following sections.

4.3.1. 50 bp psoralen-TFO ICL insert was constructed and purified

A 50 bp TFO-directed psoralen ICL migrates slowly on a denaturing 6%
polyacrylamide gel because it represents two strands linked together with a
triplex forming oligonucleotide and psoralen. We observed the psoralen-TFO ICL
at around the 150 bp (Figure 20). After purifying the UVA mediated psoralen-TFO
ICL in the 50 bp duplex DNA, we confirmed the presence of interstrand crosslink,
by using UVC photoreversal. UVC exposed ICL sample was observed to reverse
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back to monoadduct and linear 50 bp DNA (Figure 20). This is the confirmation of
the formation of the ICL.
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BbsI

BbsI
BbsI

BbsI

BbsI

pUC19N

BbsI

psoTFOpUC19ICL

Add TFO-psoralen ICL

Purify

Restriction digest

Ligate and purify

FIGURE 19. Strategy for the construction of TFO- directed psoralen ICL in
closed circular double stranded DNA.

pUC19 plasmid was modified to include a BbsI restriction digestion site. pUC19N
plasmid was constructed and purified. By restriction digestion with BbsI enzyme,
vector was created and purified. A 50 bp duplex DNA was annealed with TFO
conjugated with HMT psoralen at its 5’ end and was crosslinked by UVA
photoactivation to make ICL insert. The vector and insert were ligated in
appropriate condition to get a circular double stranded DNA with psoralen-TFO
ICL.
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A.

10#bp#ladder#
UVA#
UVA#+UVC#

B.

330#
bp#
A
KpnI
BbsI XbaI
BbsI
5' TTCGAGCTCGGTACCGAAGACATCGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGCGTGCTCTAGAGTCGACCTGCA 5'
3' AAGCTCGAGCCATGGCTTCTGTAGCTACGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACGAGATCTCAGCTGGACGT 3'

!

!!!
!
!

B

5’HMT-AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’

5’ CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 3’
3’ CGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACG 5’
!!!!!!!!!!!!!!!!!!!!!!!!
5’AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’

C

100#
bp#

psoTFO#ICL#
Monoadduct#

50#
bp#

Duplex#
DNA#

FIGURE 20. 50 bp TFO directed psoralen ICL.
A. Process of making a TFO-directed psoralen on a short duplex DNA. B. 6%
polyacrylamide gel showing the formation of the ICL, monoadduct, and remaining
duplex DNA. The conversion of ICL to monoadduct and duplex DNA by UVC
photoreversal is the confirmation of ICL formation as shown in the right lane. The
nucleotide make-up of the psoralen-TFO ICL is shown in the inset. Green
represents the nucleotides of TFO binding site. The third strand is the TFO
bound to the first two strands (duplex DNA) with Hoogsteen hydrogen bonding
represented by the asterisk (*). Gray dots represent Watson and Crick hydrogen
bonding.
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4.3.2. Vector with BbsI sites was prepared

BbsI restriction digestion sites were inserted into the pUC19N plasmid.
BbsI has unique sequences at both 5’ side and 3’ side which reduces the
chances of defective ligation. After purifying modified pUC19N, we tested if the
BbsI site is incorporated at the correct site in pUC19N plasmid by running the
BbsI digested sample on denaturing 6% polyacrylamide gel (Figure 21). A 50 bp
band was released from the pUC19N plasmid. The remaining linear pUC19N
was observed near the well.

4.3.3. Vector and psoralen-TFO ICL insert was successfully ligated in small
and then in large scale

We did several small-scale ligation reactions in order to find the best
condition that gives the highest yield of the final ligated product. Vector to insert
ratio of 1:3 to 1:5 gave high yield of ligated final product in small-scale ligation
reaction (Figure 22). A small amount of unligated or linear products and some
multimers were observed. A 1:5 vector to insert ratio was utilized, and a largescale ligation reaction was performed (Figure 23). The substrate was purified by
cesium chloride gradient to separate and purify the closed circular double
stranded DNA (Figure 23). A 35 % yield of final ligated product was obtained.
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4.3.4. Confirmation of the ICL in the final product

After the final product was purified, we tested if it retained the TFO
directed psoralen ICL. Small volume of the final product was restriction digested
with BbsI and ran on a sequencing gel. The fragment released from the
restriction digestion was the ICL fragment (Figure 24). 50 bp linear duplex DNA
was used as a control marker. This confirmed that the final ICL product is correct
and pure TFO directed psoralen interstrand crosslink in closed circular double
stranded DNA.
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A.
!

A
KpnI
BbsI XbaI
BbsI
5' TTCGAGCTCGGTACCGAAGACATCGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGCGTGCTCTAGAGTCGACCTGCA 5'
3' AAGCTCGAGCCATGGCTTCTGTAGCTACGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACGAGATCTCAGCTGGACGT 3'

!!!
!
!

B

C

5’HMT-AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’
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  pUC19N
!!!!!!!!!!!!!!!!!!!!!!!!
5’AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’
	
  

Vector

50	
  bp

FIGURE 21. Vector with BbsI sites.
A. Fragment of duplex DNA inserted between KpnI and XbaI sites in pUC19 in
order to insert BbsI restriction digestion site. Fragment with BbsI site is shown in
the inset. Blue and Red indicate the nucleotides for respective restriction
digestion sites mentioned in the diagram. Green indicates the TFO binding site.
Modified plasmid after the new insertion is called pUC19N. B. Denaturing 6%
polyacrylamide gel with restriction digested pUC19N. Linear vector is shown in
the inset and the lower band is the 50 bp fragment released for the restriction
digestion.
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FIGURE 22. Small scale ligation reaction with BbsI-vector and 50 bp psoTFO ICL.
Different ratios of vector to insert were tested to get the highest yield of the
ligated product. The final ligated product is a closed circular double-stranded
DNA with a TFO directed psoralen interstrand crosslink. Purified pUC19N and
purified vector were used as controls. The final product migrated in 1% agarose
gel similar to pUC19N (2739 bp). Some unligated linear vector and some
multimers were also observed in lesser quantity compared to the ligated closed
circular DNA.
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A.

B.

	
  

FIGURE 23. Large-scale ligation reaction of BbsI-vector and 50 bp
psoralen-TFO ICL insert.
A. Ligation reaction on a 1% agarose gel right after the ligation reaction. Most of
the products were closed circular DNA, indicated by the arrow. The bands above
the final product are linear and multimer DNA. B. Large scale ligation reaction on
a 1% agarose gel after purification by cesium chloride gradient. The linear and
multimer DNA were reduced largely after purification.

	
  

112

!

A	
  

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!5’ AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG-NH2 3’
5’CGATGCTCTTCATCCTTCCCCCCCCACCACCCCCTCCCCCTCGAAGACGC 3’
3’CGAGAAGTAGGAAGGGGGGGGTGGTGGGGGAGGGGGAGCTTCTGCGCACGAG 5’

B	
  

FIGURE 24. Confirmation of the final purified TFO- directed psoralen ICL in
a closed circular duplex DNA.
A. Diagram of the final ICL substrate with the nucleotide arrangement of TFO and
duplex DNA. Green represents the nucleotides of the TFO binding site. TFO
bound to the first two strands (duplex DNA) with Hoogsteen hydrogen bonding
represented by the asterisk (*) marks. Gray dots represent Watson and Crick
hydrogen bonding. Red represents the psoralen bridge between two thymines. B.
Restriction digested final product was run on a denaturing 6% polyacrylamide
gel. The released product ran as 50 bp psoralen-TFO products. 50 bp duplex
DNA was also used as control.
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4.4. Plasmid relaxation assay

The closed double stranded DNA is the relaxed form of the plasmid.
Experiments were performed to determine if the whole cell extracts process the
supercoiled or relaxed form of DNA substrates differently. We incubated the
plasmids in the presence and absence of whole cell extracts, and in NER
reaction buffer and ran in gels with and without ethidium bromide. We found that
the whole cell extract relaxes the plasmid within 5 minutes of incubation (Figure
25). Whole cell extracts convert the supercoiled plasmid to the relaxed plasmid,
which runs slightly faster than supercoiled plasmid in agarose gel without
ethidium bromide (Figure 25A). When gel is run with ethidium bromide, ethidium
bromide gets intercalated between the two strands of the relaxed plasmid, which
makes it run slower than the supercoiled plasmid (Figure 25B).
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FIGURE 25. Plasmid relaxation assay.

pUC19N plasmid was incubated with or without whole cell extract in an ATP
regenerating system, purified, and ran in 1% agarose gels with or without
ethidium bromide. A. 40 µg/100 mL ethidium bromide was run for 2 hours at 80
V. B. without ethidium bromide; run for 2 hours at 80 V, and stained with 40
µg/100 mL ethidium bromide for 20 minutes. pUC19N and Hyperladder were ran
as markers. SCC indicates supercoiled closed circular, RCC: relaxed closed
circular, NC: nicked circular, IR: intermediate relaxed DNA.
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FIGURE 26. 3’ Incision assay on psoralen-TFO ICL substrate.
14% sequencing gel showing 3’ incision products on upper strand with Goverhang labelling oligonucleotides to detect incision products at TFO
binding site (A), beyond TFO binding site (B) and at 3’ side on the lower
strand (C). Sequence mapping of the incision sites is shown in Figure 13.
Darker bands marked with arrows are the major incision products. M
denotes marker. Lanes with ICL substrate or with undamaged plasmid are
labelled.
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FIGURE 27. Sequence-map of the incision sites.
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Positions of incision sites are marked by the arrows and are corresponding to
and color coded with the incision products shown in Figure 12. 3’ incision sites on
the upper strand within TFO binding site are shown in (A) and beyond TFO
binding site in (B), and lower strand in (C). Green sequences are TFO and red
sequences are G-overhang oligonucleotides. Restriction digestion enzymes used
in each experiment to prepare the ends for G-overhang complementary labelling
with radiolabelled dCTPs are mentioned at respective DNA ends. Thymines
involved in psoralen ICL formation are presented as bold ‘T’. Dashes denote the
continuity of the sequences.

	
  

118

4.5. Incisions were observed on the 3’ side of psoralen-TFO ICL on both
strands

Incision assays were performed using a G-overhang oligonucleotide to
detect the incision products at the 3’ side of the ICL crosslink. G-overhang
oligonucleotides were used to detect the incisions at two different sites. One
covered the site inclusive of TFO binding site and the other covered the area
outside of TFO binding site. Incision products were not detected with the
oligonucleotide at the TFO binding site, which suggests that the incisions did not
occur at the TFO binding site (Figure 26A and 27A).

G-overhang oligonucleotide end labelling detected incision products were
represented by three dark bands and several faint bands on the upper strand.
The bands were 22, 23 and 24 oligonucleotides long, and were mapped 10, 11,
and 12 nucleotides away from the TFO, and 44, 45, and 46 nucleotides away
from the psoralen ICL (Figure 26B and 27B). These dark bands were absent on
the undamaged DNA substrate indicating that these incision products were
specific to psoralen-TFO ICL on closed circular DNA. Similarly, 3’ incision assays
were performed targeting possible incision products on the lower strand of the
psoralen-TFO ICL substrate. Several dark bands appeared in the ICL substrate
lane, which were not present in the undamaged substrate lanes. The bands were
observed as 18, 19, 20 and 21 oligonucleotides long and were mapped at 8, 9,
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and 10 nucleotides away from the ICL site (Figure 26C and 27C). The repetition
of the assays also showed several dark bands around the same sites.

4.6. Psoralen-TFO ICL was not repaired by HeLa whole cell extract

Repair assay based on the translesion synthesis at the damaged site by
the repair polymerases was performed in order to see if the incisions observed in
above experiments were for the repair-purpose. In other words, by repair assays,
we wanted to see if the human cell extract can repair TFO-directed psoralen ICL
in closed circular double stranded DNA. Repair assays were done in similar
reaction conditions as incision assays except that the reactions included
radiolabelled dNTPs to be incorporated by the polymerases for the repair. The
repaired products were restriction digested, and fragments were analysed if they
incorporated radiolabelled dNTPs. After the repair reaction, restriction digestion
enzymes (AluI and SapI) were used to create different sized fragments to make it
easier to be analysed on sequencing gel. 29 bp and a 69 bp fragments from the
restriction digestion were supposed to have incorporated more radiolabelled
dNTPs compared to neighbouring fragments and compared to undamaged DNA.
We did not observe any 29 bp bands in ICL substrate however, it was observed
in undamaged plasmid (Figure 28). SapI sequence was present at the site of
psoralen ICL. Thus it is possible that the ICL substrate was not repaired and was
resistant to SapI. Since a 69 bp band was not resolved well in a 14 %
sequencing gel, it could not be analysed.
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We performed another repair assay with the same principal as the above
repair assay except that the restriction digestion enzymes were different. This
time, we used BbsI and MluCI. A 50 bp band was supposed to have been
repaired, and have incorporated radiolabelled dNTPs as it included the site of
damage. Unlike our expectation, a 50 bp band was missing from ICL substrate
whereas other neighbouring bands; 25 bp and 68 bp bands were observed
(Figure 29). These fragments were possible only if both BbsI and MluCI cut at
their respective sites. This indicated that BbsI could cut at the designated site
and released the fragment consisting of ICL but no new dNTPs were
incorporated for repair at this fragment. Repair synthesis assay for cisplatin
substrate in HeLa whole cell extract as described earlier was used as control
assay. Control assay showed a 33 bp high intensity fragment indicating the
successful repair synthesis happening on cisplatin substrate as described earlier.
This result was reproduced in repeated experiments indicating that TFO-directed
psoralen ICL was not repaired by HeLa whole cell extract.
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A.

B.

FIGURE 28. Repair synthesis assay 1.
A. 14 % sequencing gel showing restriction digested fragments after repair
synthesis assay on psoralen-TFO ICL or pUC19N plasmid. Lanes 2, 4 and 6 are
repair reactions with ICL substrate for 30 min, 1 hr and 3 hr, and lanes 1, 3 and 5
are with undamaged DNA for 30 min, 1 hr and 3 hr respectively. B. Map of
fragments made by AluI and SapI enzymes. AT is the site of ICL formation where
SapI sequence coincides.
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FIGURE 29. Repair synthesis assay 2.
A. 14 % sequencing gel showing restriction digested fragments after repair
synthesis assay on psoralen-TFO ICL or pUC19N plasmid (Lanes 5,6) or
cisplatin intrastrand crosslink substrate (Pt) or undamaged DNA as control for Pt
substrate (Lanes 1-4) as control. Lanes 3 and 4 were performed without whole
cell extract for control. Purified DNA from repair assay with or without Pt samples
were restriction digested with BstN1 (lanes 1-4) and with or without ICL substrate
was restriction digested with BbsI and MluCI (Lanes 5 and 6). B. Map of
fragments created by BbsI and MluCI on ICL substrate.
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Chapter 5. Discussion

5.1. Consequences of XPA disruption in human cells

5.1.1. Expression of a subset of genes is influenced by XPA status in cell
lines

The major purpose of this study was to determine the extent to which
XPA status may influence transcriptional activity in cells. As we show here,
expression of a restricted subset of genes is reproducibly affected by XPA status.
These include genes that are necessary for steroid metabolism and for optimal
mitochondrial function and integrity.

A plausible explanation for a positive effect of XPA on gene expression is
that XPA acts as part of a transcription factor complex, for this subset of genes.
For example, by binding to DNA and proteins in concert with the transcription
initiation factor TFIIH and other NER proteins, it may modulate TFIIH activity for a
subset of genes. As XPA is a DNA binding protein, it might also serve as a
component of an enhancer or mediator complex for some genes.

Another, not necessarily exclusive possibility is that the NER defect
caused by XPA deficiency gives rise to constitutive DNA damage stress that
interferes with transcription of some genes. Persistent sites of DNA damage on
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templates will interfere with transcription. For individual genes that are more
susceptible to DNA damage, this could account for the higher transcription of
some genes in XPA-proficient cells. Graphic explanation of some possible
mechanisms by which XPA may be involved in transcription is presented as a
model in Figure 30.

What are possible sources of DNA damage that would result in
constitutive stress for XPA defective cells? A low yield of UV radiation-induced
pyrimidine dimers could potentially accumulate in XPA-defective cells from UVA
radiation that can penetrate plastic dish lids. However, we take care to culture
cells in low ambient light or with yellow fluorescent lights, and this seems unlikely
to be a significant source of stress to explain our data. A ubiquitous and
constitutive source of damage is the lesions caused by reactive oxygen species,
constantly produced in cells. Reactive oxygen species induce many lesions that
are largely repaired by XPA-independent BER. However, one type of oxidative
damage, the 8,5'-cyclopurine-2'-deoxynucleosides (cyclopurines), are repaired by
NER but not by BER (78, 79). These lesions are known to interfere with
transcription.

Oxidative damage, particularly cyclopurine lesions, has been previously
suggested as an explanation for the neurodegeneration in XP patients (76, 78,
120), which includes progressive cerebral atrophy and hearing loss. Most
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neurons are non-replicating and metabolically very active, depending on
mitochondria to remain functional.

On the other hand, there are contradictions about oxidative damage
accumulation in XPA mutant causing of neurodegeneration and accelerated
aging as shown by studies in C. elegans (121). Deficiency of XPA did show
accumulation of oxidised base like formamidopyrimidines (122) however, xpa-1
mutants were found to have normal life span (121, 123). This study suggests that
there may be mechanism other than defect in DNA repair in XP patients that
causes neurodegeneration and accelerated aging.

A more direct connection between an increased load of DNA damage and
mitochondrial dysfunction is also possible. There are several examples of this. In
mice, a telomerase defect eventually gives rise to exposed telomeres. This
genomic stress is clearly associated with mitochondrial dysfunction, and it is
possible that exposed DNA ends mimicking a DSB induce a signal for disruption
of key mitochondrial genes (124). An siRNA screen for factors that reduce
sensitivity to a mitochondria-targeted DNA damaging agent provides another
example (125). A diversity of different DNA repair factors, including XPA were
detected in this screen.

With an increased load of DNA damage, transcription may be delayed
because template damage interferes with transcript elongation. A second
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consideration is that transcription and NER are competing processes. For
example, transcription initiation efficiencies in yeast are reduced when NER is
ongoing (126). In mammalian cells, there is lower NER activity at promoters
when core transcription factors are bound to them (127, 128). After UV radiation
damage to DNA, NER proteins are delayed in recruitment to promoter sites by
several hours (81). This suggests that NER proteins are prioritized to repair
damaged DNA first before resuming any activity in transcription.

5.1.2. Defective mitophagy associated with XPA deficiency and relation to
neurological deficits

It has been observed that some of the symptoms of xeroderma
pigmentosum group A have commonalities with mitochondrial disorders (82).
Their study showed in human cells defective of XPA protein, mitochondrial
functions like mitochondrial membrane potential, membrane organization and
oxidoreductase activity were abnormal. XPA was reported to play a role in the
regulation of mitochondrial autophagy and mitochondrial functions through
NAD+/SIRT1 and PARP (82). In the present study, we found that genes 1.5 fold
or more changed in XPA+ compared to XPA- were indeed significantly
represented for many mitochondrial and mitophagy-related GO terms (Table 4).

Mitochondrial defects and mitophagy are directly related to neurological
functions. About 25 % of xeroderma pigmentosum patients develop
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neurodegeneration in later life. The progressive neurodegeneration includes
intellectual defects, hearing impairment, abnormal speech, neuropathy and
muscular discoordination for movements of hands and legs (129). In a study of
XP patients from 1971-2009, 6 out of 10 patients with XP-A and 16 out of 23
patients with XP-D had neurological degeneration (129). The cause of the death
of many XP-A patients was also neurological degeneration (129-131).

One possible reason for this phenotype is the accumulated DNA damage
in metabolically active but non-dividing neurons (57, 129), whereas some study
in C. elegans show that xpa-1 mutant, although accumulate oxidative damage,
do have normal life span (122, 123). Other recent study shows that the xpa-1
mutant old worms have higher amount of NAD+ production due to increase in
PAPRylation, which may due to the mitochondrial dysfunction (82). This result
suggests that there is a relation of old-age with mitochondrial dysfunction, which
is more prominent in XPA deficient condition. Overall, these studies suggest that
XPA may have role in maintenance of mitochondrial functions and consequently
neurological functions.

5.1.3. The most significant XPA-regulated genes may explain steroid and
sexual degeneration issues in xeroderma pigmentosum group A

The genes that are uniformly altered with the highest magnitude and
significance are AKR1C1 and AKR1C2. These genes are critical for steroid
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metabolism and some bile metabolism (132-134). AKR1C1 converts
progesterone to its inactive form, 20-alpha-dihydroxyprogesterone. AKR1C2
catalyzes the inactivation of the most potent androgen, 5-alphadihydrotestosterone, to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol).
Therefore, an imbalance of steroid hormones may be expected in XPA-defective
cells. Both genes are indeed associated with obesity, sex reversal, hyperphasia
and developmental delays (135, 136). A previous study using microarray analysis
to study gene expression changes in XPA-defective cells (82). We analyzed the
most XPA-dependent genes found in this microarray analysis (NCBI GEO
dataset GSE55486) and compared it to our list of most changed genes. AKR1C2
was the only gene that coincides with our list of most changed genes by RNASeq analysis. We confirmed that XPA-deficient cells have exceptionally low
levels of AKR1C1 and AKR1C2 at the protein level, compared to proficient cells.
This was true in both fibroblasts and HeLa cells.

Our finding of XPA-dependent expression of the steroid regulator AKR1C1
and AKR1C2 gene products may be highly relevant to the sterility and sexual
developmental issues observed in XPA-deficient mice (137). Degenerating
seminiferous tubules and no spermatozoa were detected in 24 month old XPA-/mice (137). Secondary sexual development is delayed in some XP patients
(138). Consequently, our finding of XPA-dependent expression of the steroid
regulators AKR1C1 and AKR1C2 may be highly relevant to the sterility and
sexual developmental issues observed in mammals.
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5.1.4. Multiple non-isogenic cell lines improve the analysis of RNA-Seq data

Despite these correlations, there are many unanswered questions concerning the
mechanism of how XPA affects mitochondrial function. One puzzle is that
although mitochondrial functions are affected, the specific gene transcripts that
are affected are different in each cell line pair. Our current study shows how
important it is to not only have biological replicates for RNA-Seq, but also to
investigate cell lines of different genetic background in order to uncover the most
significant effects of a single gene disruption.

5.1.5. Possible additional role of XPA may not be related to NER

It is significant that the XPA-dependent transcriptional profiles in KO142
and KO48 cells are similar, even though KO142 cells retain about 10% of the
XPA protein level found in HeLa cells. The amount of XPA present in the KO142
line is enough to confer near-normal UV sensitivity, consistent with previous
findings that XPA is in excess in cells for NER activity (116). Because complete
knockout of XPA or knockdown to 10% has a similar effect on transcription, this
suggests that at least part of the influence of XPA on transcription is not directly
related to the NER function.
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5.1.6. Cause of XPA instability in KO142

We checked if the loss of XPA protein in KO142 is due to the proteasomal
degradation. Our result did not indicate such possibility although this study needs
to be repeated with proper control for proteosomal degradation. Another cause of
less XPA in KO142 may be due to the alternative splicing. The six amino acid
deletion may have created an exonic splicing enhancer or disrupt exonic splicing
silencer that could lead to an activation of alternative spicing site causing some
exon skipping. This can be tested by PCR using one primer at Exon 1 and other
one at different positions on exons beyond hypothesised splice sites. The
products can be run in gel to compare the products from different pairs of
primers.
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FIGURE 30. Model: Possible mechanism by which XPA is involved in
transcription.

1. XPA may be involved in transcription by its interaction with TFIIH. 2. XPA may
directly bind to the promoter to directly play role in transcription. 3. XPA may bind
to the enhancer region and be involved in transcription as a co-activator. 4. Due
to unavailability of XPA for the DNA repair at the promoter site, transcription may
be obstructed or delayed.
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5.1.7. Future directions

5.1.7.1. Validation of RNA-Seq results by immunoblotting and CHIP

This study is the initial effort to get an idea of the extent of transcriptome
changes in XPA-defective human cells. Our result shows that a small percentage
of genes is affected by the XPA status. We found by RNA-Seq analysis that a
high percentage of affected genes represented specific functions related to
mitochondrial regulation and pathways related to neurological functions. We
validated some of the important genes from RNA-Seq result at protein level and
verified 2 of the three tested targets. However, this is only a small percentage of
genes out of 27 highly differentially expressed genes in XPA- vs. XPA+. In the
future, it will be valuable to check all of the 27 genes at the protein level.

Another way of validating the results from RNA-Seq will be to perform a
chromatin immunoprecipitation (ChIP) assay at the promoter sites of the highly
differentially expressed genes like AKR1C1, AKR1C2, and more genes of
interest, to see if XPA is present at the promoter sites of these genes. This will
give an idea about the mechanism how XPA is involved in the transcription.
Since it has also been observed that in retinoic acid transactivated conditions,
not only XPA but many other NER proteins were also found at the promoter

	
  

133

regions of few genes (81), it will be worth to look at if other NER proteins can
also be pulled down.

The cell lines we used in our study are immortalized or cancer cell lines. It
is important to get similar results in the primary cell lines as well to make sure the
change in the genes are not related to the immortalization. Validations of the
highly differential genes by similar methods as mentioned above can be done in
the XPA deficient primary cell (skin fibroblasts) lines and normal human skin
fibroblast as control. Comparison with primary cells from other XP groups would
confirm that the changes are XPA-specific.

5.1.7.2. Analyzing differentially expressed genes in XPA deficient mice

In XPA-deficient mouse models, male sterility was one of the characteristics
noted (139). However it not known whether the XPA-dependent genes that we
found by RNA-Seq are involved in phenotypes of such mice. As AKR1C2
deficiency is found to be one of the causes for the reversal of sexual orientation
and sterility (140), it will be valuable information to look for AKR1C2 and other
genes of our interest in tissues of XPA deficient mouse models.

5.1.7.3. Biochemical assays for mitochondrial and metabolic functions in
XPA deficient and proficient cells
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Since we found metabolic and mitochondrial pathways being represented
by significant differentially expressed genes in our analysis, XPA may have a role
in metabolism or mitochondrial maintenance. It is worth looking into more details
of XPA being involved in mitochondrial functions by performing biochemical
assays. Monitoring ATP generation, mitochondrial membrane potential, ROS
formation and biochemical metabolic reactions such as reduction of aldehydeketone compounds in XPA deficient cells compared to the proficient, can be done
for the further insight in the study. Immunofluorescent assays can also be done
to compare the expression of these genes like NDUFA4L2 (NADH
Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex, 4-Like 2) compared to XPA
status.
Although it needs more study, we obtained some preliminary results for
the influence of XPA status on mitochondrial functions. We performed
biochemical assays to detect the mitochondrial mass, mitochondrial membrane
potential defect and amount of ROS levels in XPA proficient and deficient cell
lines. Following assays were performed in collaboration with Dr. Miao-der Chen
in Bratton laboratory.

Mitochondrial mass:
To determine whether the mitochondrial dysfunction obtained suggested
by expression pathway analysis is due to a low mitochondrial mass in XPA
deficient cells, we looked at the total mitochondrial mass in all cells. Cells were
treated with TMRE (tetramethylrhodamine, ethyl ester) dye for 5 min at 37 °C,
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washed with PBS and subjected to Flow cytometer (Accuri C6 Flowcytometer)
using FL3 fluorescence channel and 8000 events (141). TMRE is a positively
charged red dye that is accumulated easily in mitochondria due to its negative
charge. Depolarized or inactive mitochondria have low membrane potential and
are unable to pump in the dye (142). We observed no difference in the total
fluorescence count (total populations) in XPA proficient and deficient cells except
slight lower count in XP12RO compared to XPA/XP12RO cells (Figure 31A). This
result indicated that there is no difference in number of mitochondria in XPA
proficient and deficient cells. Cells not treated with TMRE were used as negative
control and they were observed as population without fluorescent counts. This
assay needs to be repeated to confirm the result.

Mitochondrial membrane potential defect:
To confirm the result about defect in mitochondrial membrane potential in
XPA deficient cells from the pathway analysis, we performed similar assay as
described above and looked at the population that could not pump in TMRE in
the mitochondria. This population represents the defect in membrane potential
(143). We observed that XPA deficient cells have higher percentage of
population that has defect in mitochondrial membrane potential compared to the
proficient cells. This population has low mitochondrial membrane potential
(Figure 31B). Similar negative control was used as mentioned above. This assay
needs to be repeated for the confirmation of the result.

	
  

136

ROS levels:
Higher ROS production is one of the factors observed when there is defect
(high) in mitochondrial membrane potential. We performed an assay where a
reagent (CM-H2DCFDA) for indicator of ROS was used in cell culture at 37 °C
for 15 min. It turns to fluorescent compound DCF after oxidation, which was
measured by flow cytometer at fluorescent channel FL1 and 8000 events. Cells
not treated with CM-H2DCFDA were used as negative control. We did not
observe difference or only little lower ROS in XPA deficient cells compared to the
proficient cells (Figure 31C) which is relevant to the lower mitochondrial
membrane potential observed in Figure 31B. This result indicated that the cells
are not going through the oxidative stress. This assay needs to be repeated for
the confirmation of the result.

Our preliminary results mentioned above contradict with the recent study
in XPA deficient human cell lines showing the increased mitochondrial potential
and ROS levels in XPA deficient cells (82). If our result is true about lower or no
difference in ROS level in XPA deficient cells, it could be because the XPA
deficiency is not causing problem for repairing of the oxidative damages, as BER
is efficient enough to repair most of the oxidative damages.

Both low and high mitochondrial potential are defective for cells as they
have abnormal physiological consequences (144, 145). If our result about lower
mitochondrial membrane potential in XPA deficient cells compared to XPA
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proficient cells is true, it may indicate that the XPA deficient cells are going
through low generation of ATP or low oxidative phosphorylation. This explanation
also concurs with the high fold change (1.5 - 7) in NDUFA4L2 gene in XPA
proficient cells compared to the deficient. This result suggests that XPA may play
role in metabolism by maintaining mitochondrial membrane potential.
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FIGURE 31. Mitochondrial assays.
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A. Mitochondrial mass was measured by the fluorescent count produced by the
uptake of TMRE dye in the mitochondria. B. Defect in mitochondrial membrane
potential was measured as indicated by the population in the flow cytometer read
that were unable to sequester TMRE dye in the mitochondria by the membrane
potential pump. C. Level of ROS in the cells was measured as indicated by the
fluorescent count produced due to the oxidation of CM-H2DCFDA in to DCF.
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5.1.7.4. Analyzing brain tissues of XPA deficient mice and patients with
neurological diseases

Similarly, we observed many genes and pathways responsible for
neurological functions. It is also important to explore XPA in vivo analysis. This
can be studied in brain tissues of XPA deficient mice in absence of any external
DNA damage and also observe these changes regarding some of the
neurological genes such as WFDC21P, LHX2, HOMER2 and others we observe
as highly expressed in XPA proficient cells. Immunofluorescent assays on brain
tissues for the expression of these genes compared to XPA will be helpful to
understand the effect of XPA status in neurological functions. Alternatively, tissue
samples from patients with Alzheimer’s or Parkinson or Huntington disease can
be analyzed for the expression of XPA. The result will be helpful in further
discussing on the cause of neurological defects in XPA patients.

5.2. Processing of TFO-directed psoralen interstrand crosslink in human
cell extracts

5.2.1. Psoralen-TFO ICL or TFO as an adduct for NER

The enzymatic processing of a TFO-directed psoralen ICL in closed
circular double stranded DNA has not been studied previously human cells. It is
highly possible that it is a substrate for NER in human cells as the mutation
caused by TFO was found to be dependent on NER (146). In non-replicating
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conditions, damage in DNA is recognized by NER as distortion to DNA structure.
Psoralen causes enough distortion in duplex DNA, which makes it a substrate of
nucleotide excision repair, even though the distortion is less than other ICL
causing agents such as cisplatin (22). It makes a large 55.8° buckle in the d (T.A)
base pair with thymine on the pyrone strand. This results in a steric collision of
the O4 of thymine and pyrone ring, resulting in destruction of Watson and Crick
hydrogen bond between the base pairs (147). We used the TFO conjugated
psoralen primarily to construct a site specific ICL. However, since both psoralen
and TFOs may be substrates for NER, we expected the processing of TFO
directed psoralen ICL substrate may be dependent on NER. The addition of TFO
to psoralen may cause even more degree of distortion compared to that caused
by TFO or psoralen alone. This may be the reason why we observed incisions
only beyond the TFO binding site on the strand (upper), where TFO is bound to
the DNA. On this strand, incision products were observed 44 nucleotides away
from the ICL site, which were beyond TFO binding site. These incisions were 9
nucleotides or farther from the 3’ end of the TFO, which is relevant to the
distance of 3’ side incisions observed with cisplatin intrastrand adduct in human
cells (102). We also tried to detect incision products within TFO binding site, but
we were unable to find any incisions within TFO binding site. This result may be
the indication that TFOs are substrates for the nucleotide excision repair pathway.

5.2.2. TFO-directed psoralen ICL was not repaired by HeLa whole cell
extract

	
  

142

We observed incisions at the 3’ side of TFO-directed psoralen ICLs but we
were unable to detect repair in human cell extract. We did not find incorporation
of radiolabelled dNTPs at the ICL site, which was indicated by the disappearance
of the fragment containing the ICL in the damaged DNA substrate compared to
the undamaged DNA substrate. In one of our repair assays, we used a restriction
site that coincides with the ICL formation site, which makes the ICL substrate
resistant to the restriction digestion by SapI. 29 bp and 69 bp fragments were
supposed to be released if SapI and AluI cut at their sites. We found the
disappearance of the 29 bp on ICL substrate whereas we could not confirm
similar result for the 69 bp fragment, as it appeared to be coinciding with other
bands (64 and 67 bp) on the gel.

We designed another repair assay with different restriction digestion sites.
Since we were confident that BbsI cuts and releases the 50 bp ICL fragment, we
used BbsI and one other site, MluCI, to create multiple bands to make the
comparison of intensity of the fragments more efficient. In this assay also, we
found the ICL containing fragment (50 bp) was not observed on the ICL substrate,
whereas it was observed on the undamaged plasmid. Since all other neighboring
bands were also observed in both damaged and undamaged DNA, the restriction
digestion was successful with both enzymes but the 50 bp ICL fragment was not
replaced with the radiolabeled dNTPs. This result suggests an unsuccessful
repair of the psoralen-TFO ICL in HeLa whole cell extracts.
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This turns our attention towards the question whether the incisions we
observed in human whole cell extracts are repair-related. If they are not for the
purpose of repair, why are the incisions made? It could be that the cell extracts
cannot proceed beyond incision to complete the repair on psoralen-TFO ICL.
However in mammalian cells, previous studies have indicated the repair of TFO
or psoralen ICL or psoralen-TFO ICL. TFO-induced mutation was dependent on
NER (XPA) (146), and thus TFOs are possibly repaired by human cells. Psoralen
ICLs are also repaired in human cells as shown by reporter assays (148). TFOdirected psoralen in mammalian cells has shown to cause a higher degree of
mutation compared to spontaneous mutation (149), indicating its recovery.
However, no study has been done so far to study the repair of psoralen-TFO ICL
in human cell extract. If TFO-directed psoralen ICLs are not repaired by the
whole cell extracts, but are repaired in human cells, it may be because they are
processed beyond incision by other DNA repair enzymes besides NER proteins.
Recently it has been reported that NEIL3 glycosylase is involved in unhooking of
psoralen ICL in xenopus egg extract in incision independent way (150). When Nglycosyl bond cleavage is inhibited, the incisions were produced in a FANCI-D2
dependent manner (replicating system), indicating that the NEIL3 unhooking is
the preferred way of processing psoralen ICLs in vertebrate cell free system.
Thus it may be possible that psoralen-TFO ICLs are also processed by NEIL3 at
the unhooking step. In absence of this step in processing, repair may not have
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occurred in HeLa whole cell extract. The possible mechanism by which psoralenTFO ICLs are processed in human cells is represented as a model in Figure 32.

5.2.3. TFO in targeted DNA damage and gene alteration

We have not tested the difference between incision products with psoralen
only and psoralen-TFO ICL. If it is true as observed in E.coli where TFO resulted
in more incision products than psoralen ICL only (25), psoralen-TFO ICL may be
more effective in chemotherapy to kill cancer cells through DNA damage. Thus,
determining the mechanism of TFO-directed psoralen-DNA ICL is an important
step towards improving chemotherapy.

Currently, due to lack of specific targets, chemotherapies are not being
effective. TFOs can be used to target specific genes, like oncogenes, to disrupt
them or to deliver targeted drugs like antimetabolites to specific sites to cause
cytotoxic effects in cancer cells (151). Since TFOs bind to specific sequences of
the genome and with high affinity, it has been put forward as an option for
altering targeted sequences (152-155). It can lead to improving the cure and
treatment of different genetic diseases. There is an abundance of TFO-binding
homopurine or homopyrimidine rich sequences present in human genome (156),
giving a good platform for TFO-targeting treatment. TFOs can be used in
conjugation with DNA damaging agents, such as ICL causing agents or photo
induced endonucleases (157) for the targeted effects. The concept of TFO
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conjugated drug therapy is still not implemented in humans. In mice, cells
transfected with TFO conjugated with a cytotoxic drugs was delivered to treat
tumors, and was successful in reducing the tumor load (151). Similar strategy
can be used to deliver TFOs, TFO conjugated drugs, or DNA damaging agents in
cancer patients. However, since it is not exactly known about the mechanism of
processing of TFO or TFO conjugated psoralen, the results from TFO-targeting
therapy will be highly unpredictable.

5.2.4. ICL substrate in a closed circular double stranded DNA

Most of the efforts to study the processing of ICL were done with ICL in
short duplex DNA. Since the duplex DNA has open ends, it is possible to be
processed by unspecific nucleases available in the cell extract. To avoid the
artifacts and confusions of processing of ICL due to the accessibility of the free
ends, we constructed ICL in closed circular double stranded DNA and purified
high-yield of the final product. It was also important to purify ICL products from
the monoadducts, which are formed during the photoactivation of psoralen. It
was even more challenging to do this purification with closed circular double
stranded DNA. Thus we first made ICL in short duplex DNA, purified in
denaturing condition as covalent bonding in ICL cannot be separated by
denaturing while DNA with monoadducts can be separated to single stranded
DNA. Short duplex DNA with ICL purified by this strategy was efficiently ligated to
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the vector with unique DNA ends (BbsI) to confirm the correct orientation of the
ligation.
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FIGURE 32. Model: Possible mechanisms of psoralen-TFO ICL repair in
human cells.

The damage is recognized and incisions are made around the psoralen-TFO ICL,
which may be dependent on NER. The gap created by incisions is repaired by
translesion synthesis. In the later step of repair, unhooked structure is formed
which may be cleaved by NEIL3 followed by repair by DNA polymerase and
ligase.
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5.2.5. Future directions

5.2.5.1. Incision assay with NER deficient cells complementation with
purified XPA protein

There are some indications from the previous studies that the incisions we
observed with the psoralen-TFO ICLs may be dependent on NER. However, we
have not ruled this out for certain. The important study to do in the future will be
to confirm this with NER deficient whole cell extracts and complement with the
purified NER protein. XPA deficient whole cell extracts from KO38 cells will be
made, and the incision reactions will be performed as described earlier, with or
without addition of XPA purified protein.

5.2.5.2. Detection of 5’ side incisions

We looked for the incision products only at the 3’ side of the adduct, on
both strands. Detection of the incisions at the 5’ side of the psoralen-TFO ICL, in
similar process as we detected 3’ incision sites, is a challenge due to the
direction of the polymerase activity and the limited restriction digestion sites
available on the plasmid. An effective plan should be developed to detect the
incision products at the 5’ side as well. Only after confirming that the incisions
occur on this ICL substrate at both sides of the adduct, we could be more close
to understanding if the processing of the TFO-directed psoralen ICL in closed
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circular double stranded DNA is by NER. Some strategies are presented as
follows: 1). Design a G-overhang oligonucleotide complementing incision product
around between ICL and ClaI. This is only 10 bp long distance, which may be too
short to cover the incision site at 5’ side of the ICL. Another G-overhang can be
designed around EcoRI, which is 37 bp away from the ICL, and may be too far to
cover the incision site. However we have not tried this and it may be worth trying.
2). In another strategy an oligonucleotide can be designed in which its 3’ end
coincides with the 5’ end of EcoRI, a restriction digestion site 37 bp away at the 5’
side of the ICL. The coinciding of the ends is important to exactly map the size of
the incision product. The oligo should be long enough to cover the incisions close
to 5’ side of the ICL. This oligo will be radiolabelled at its 3’ end. After the incision
reaction of the DNA substrates, they will be purified, denatured, and annealed
with radiolabelled oligonucleotide. A single strand specific nuclease will be used
to digest the 3’ overhang resulting in the duplex DNA of same size as the incision
product and will be detected in sequencing gel (Figure 33).

5.2.5.3. Incision assays with or without TFO

Our results from the incision assay on psoralen-TFO indicated that TFO
may be substrate for the incision reaction, but to differentiate if psoralen ICL and
TFO-psoralen ICL are processed differently, TFO has to be removed after
interstrand crosslink with psoralen is formed and the similar incision assays need
to be performed and analyzed. A strategy as described in Christensen et al, 2008
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can be used for this purpose (25). TFO and psoralen can be bound to a disulfide
bond that can be easily removed after ICL is formed, by treating with DTT at
60°C for few hours (158).

5.2.5.4. Involvement of NEIL3 in the processing of psoralen-TFO ICL

NER proficient whole cell extract could not repair psoralen-TFO ICL in our
experiments. It may be possible that other repair pathways are involved in the
processing of the ICL substrate that the whole cell extract we prepared are not
proficient in. Recently it has been reported that NEIL was cleaves the unhooked
structure of psoralen ICL in incision independent manner (150). It is worth to
check if psoralen TFO is also unhooked by NEIL3 after initial incisions are made.
The reaction can be done following the protocol in Liu. M, et al, 2009 (159).
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FIGURE 33. Strategy to detect incisions at the 5’ side of the ICL on the
upper strand.

After the incision reaction, a 3’ radiolabelled oligo will be annealed to the purified
and denatured DNA intermediate products of control substrate and ICL substrate
indicated in the figure. A single strand specific nuclease will be used to digest the
overhang of the oligo at 5’ side. The remaining fragment will be detected on a
sequencing gel.
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